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The 21st century has seen a dramatic acceleration in the evolution of bacterial resistance.  
Many classes of commercial antibiotics, including most current commercial β-lactams, were 
structurally optimized to counter 20th century pathogens.  The carbapenems represent the most 
potent and broadest spectrum of the β-lactams, representing crucial last line agents to treat life-
threatening infections.  While the 21st century has seen the appearance of carbapenem-resistant 
strains, the basic substitution pattern of commercial carbapenem antibiotics has remained constant, 
other than minor modifications at the C2 position.  This research will investigate whether 
substitution at an atypical carbapenem position, the C5 position, can improve the antibiotic’s 
potency against resistant pathogens, particularly including Mycobacterium tuberculosis, 
Mycobacterium abscessus and Acinetobacter baumannii.   This project produced improved 
synthetic methodology to generate this atypically substituted class of carbapenem, helped define 
the effect of substituents at this position on the carbapenemase susceptibility and binding to
 transpeptidase targets, and demonstrated that selected C5-substituted carbapenems can be superior 
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Not surprisingly, under constant antibiotic pressure, bacteria are developing unprecedented 
levels of antibiotic resistance.   Carbapenem antibiotics represent the most potent of the β-lactam 
class. The carbapenems were structurally optimized in the 1970s and 1980s to treat pathogens of 
that era.  Bacterial mechanisms of antibiotic resistance have evolved substantially in the past 40 to 
50 years, and it is time to reevaluate crucial structure-activity relationships (SARs) to determine 
whether selective modifications can improve efficacy. Carbapenems are delicate molecules, 
generated by total synthesis.  Current commercial carbapenem antibiotics are simple C2 
derivatives of a common scaffold.  Atypical modifications (i.e. non-C2) are particularly 
synthetically challenging.  The objective of this research is to prepare atypically substituted 
carbapenem antibiotics and, in collaboration with numerous investigators, both industrial and 
academic, determine the potential for improvement in activity in treatment of selected 21st century 
pathogens, particularly including Mycobacterium tuberculosis, Mycobacterium abscessus, and 
Gram-negative pathogens including Enterobacteriaceae, Pseudomonas aeruginosa, and 
Acinetobacter baumannii.  In addition to inherent antimicrobial efficacy, our collaborators are 
capable of evaluating outer membrane porin penetration, penicillin-binding (target) affinity, and 
β-lactamase (carbapenemase) susceptibility, prospectively enabling us to develop structure porin 
permeability relationships (SPPRs), structure target affinity relationships (STARs), and structure 
carbapenemase susceptibility relationships (SCSRs) of the carbapenem scaffold. 
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Gram-negative bacteria, Gram-positive bacteria, and Mycobacteria have developed 
resistance to antibiotics through β-lactamases, efflux pumps, and penicillin-binding-protein (PBP) 
modifications. This antibiotic resistance is particularly troublesome in the case of Gram-negative 
bacteria due to the presence of an outer membrane and sequestered periplasmic space that provides 
them with additional defenses against incoming antibiotics. Gram-negative bacteria Acinetobacter 
spp and Pseudomonas aeruginosa cause hospital-acquired infections with mortality rates as high 
as 43% and 18-61%, respectively, in the United States. 22 Several strains of Enterobacteriaceae, a 
large family of Gram-negative bacteria that include some common pathogens, have been found to 
have multi-drug antibiotic resistance and pan-resistance, i.e. resistance to all known antibiotics. 
Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus faecium, have also been found to develop resistance to many 
antibiotics. Mycobacterium tuberculosis (Mtb), the pathogen responsible for tuberculosis (TB), is 
another problematic pathogen due to its special L,D transpeptidase.15 TB affects one fourth of the 
world’s population and in 2016, there are 1.3 million TΒ-related deaths recorded in 2017. TB is 
one of the top 10 causes of death and a leading killer of individuals simultaneously infected with 
HIV. 6 
 
Today’s most commonly prescribed antibiotics are the β-lactams, which target bacterial 
cell wall biosynthesis. Therefore, one way to address the problem of resistance is to structurally 
modify β-lactams to overcome the resistance mechanisms of bacteria. Carbapenems are a class of 
β-lactams that have the broadest spectrum of activity against Gram-negative, Gram-positive, and 
Mycobacterium species, thus are referred to as “last-line agents” or antibiotics of last resort. 
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Characterized by C1β-methyl group and a substituted sulfur at C2, past studies have extensively 
explored carbapenems with different side chains at C2. Based on examination of existing 
crystallographic studies of carbapenem antibiotics with their targets, the PBP transpeptidases, and 
with numerous β-lactamases, we decided to try an alternative approach and explore the effect of 
carbapenem antibiotics with a substituent other than hydrogen at the C5 position.  Even small 
modifications in structure can improve properties, and it is noted that very early studies had shown 
that the addition of the methyl group to the C1 position made a significant difference in the 
carbapenem antibacterial-spectrum, and enhanced stability towards β-lactamase and human renal 
dehydropeptidase, DHP-1. 33 
In this study, atypical substitutions of carbapenems were explored to design better 
antibiotics for the 21st century evolved pathogens. This was done by looking at previously made 
carbapenems, understanding which functional groups add stability to the compound, and 
understanding which carbon positions make a difference to synthesize drugs with improved 
permeability, stability against β-lactamases, and stability to efflux pump mediated extrusion. Our 
research discovered an atypical modification of carbapenem that decreased minimum inhibitory 
concentration (MIC) of Mtb and Mab (combined with clavulanic acid) compared to meropenem. 
Our research is still exploring and synthesizing new carbapenems (discussed below). 
 
The Bacterial Cell Envelope  
Bacteria maintain and shape their cell envelopes to shelter them against stresses they 
encounter, allowing them to grow as needed and to reproduce.  Depending on the cell envelope 
composition, most bacteria are classified as either Gram-negative or Gram-positive bacteria. 
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However, some cell envelopes are more complex and have the characteristics of both Gram-
negative and Gram-positive cell walls, such as that of Mycobacteria. 1, 37 
 
Gram-Negative Bacteria 
The cell envelope of Gram-negative (GN) bacteria (Figure 1) is composed of the outer 
membrane (OM), the inner membrane (IM), the periplasmic space between these two membranes, 
and the peptidoglycan cell wall, located in the periplasm. The relatively thin GN cell wall is made 
out of thin mesh of peptidoglycan. The OM excludes toxins and provides stabilization to the 
organism. There are two types of OM proteins, which include lipoproteins (non-transmembrane) 
and β-barrel proteins (transmembrane). The β-barrel proteins (such as porins, OmpF, and OmpC) 
allow the diffusion of small molecules, limiting the hydrophilic molecules < 700 Da. The IM is a 
protective barrier (especially for hydrophobic molecules) composed of lipopolysaccharide (LPS), 
which is a glucosamine disaccharide with polysaccharide chain, approximately seven saturated 
acyl chains, and a polysaccharide core. The periplasm is established in an aqueous cellular 
compartment between OM and IM . Proteins are synthesized in the cytoplasm, and then are 
transferred to the IM, OM or periplasm. The shape of Gram-negative bacteria varies from rod 




Figure 1. Diagram of Gram-negative and Gram-positive bacteria cell envelope. It shows 1) the 
outer membrane, including the porins. 2) periplasmic space, including the lipoprotein that 
peptidoglycan. 3) and the inner cell membrane for Gram-negative.46 Also, shows the lipoprotein 
that peptidoglycan and the inner cell membrane, with no outer membrane for Gram-positive. 46 
 
Gram-Positive Bacteria 
Unlike Gram-negative bacteria, Gram-positive bacteria (Figure 1) do not have an 
OM.   The thick GP cell wall consists of layers of peptidoglycan with anionic polymers 
through the layers. The anionic polymer is called teichoic acid, which differs in 
composition based on the bacterial species. Some are made out of glycerol phosphate, 
glucosyl phosphate, and ribitol phosphate polymers, and the makeup 60% of the Gram-
positive cell wall. The peptidoglycan in Gram-positive bacteria also differs from Gram-
negative with the nature of the peptide crosslinks, where the peptides are connected through 
pentaglycine branch. The branch stem peptides are very important to Gram-positive 
bacteria as they are the attachment site for proteins. Also, these stem peptides can be 
modified leading to resistance to the β-lactam antibiotics. 36, 37 
 





The cell envelopes of Mycobacteria (Figure 2), such as Mtb, are very complex and have 
the characteristics of both Gram-positive and Gram-negative bacteria. They have an OM (with 
porins), IM, and peptidoglycan cell wall. The peptidoglycan layer surrounds the IM, and it has 
arabinogalactan that is covalently attached to mycolic acids. The mycolic acids are fatty acids that 
contain highly long alkyl groups that can reach as much as 90 carbons, and they are very important 
to the OM. These fatty acids maintain a rigid cell shape, and protect the cell from hydrophobic 
antibiotics.  As mentioned above, Mtb and Mab have L,D-transpeptidase with (33) linkage, which 
plays a role in drug-resistance. 37, 35, 9 
 
Figure 2. Diagram of mycobacterium in general showing mycolic acids, porin, peptidoglycan 
and cell membrane.46 
Penicillin-binding Proteins (PBPs) 
Penicillin-binding proteins, or PBPs, are enzymes involved in cell wall biosynthesis. They 
are a subgroup enzymes of transpeptidases called serine D,D transpeptidases. They catalyze the 
 
 7 
formation of cross-linked peptidoglycan by the linkages between the fourth and third residues of 
two adjacent peptide side chains (4 3 linkage) as a final step for the bacteria to form 
peptidoglycan. Peptidoglycan is constituted of β-linked N-acetylglucosamine (GlCNAc) and N-
acetylmuramic acid (MurNac) polysaccharide chains cross-linked through peptide chains. It serves 
as a three-dimensional “net” that protects the cell by lining the exterior of the cell membrane 
(Figure 3). It is very important to the cell as it has multiple functions including cell wall synthesis, 
cell division, determination of the shape of the bacteria’s cell, attachment site for virulence factors, 
helping the bacteria in morphological transformation when it is under stress, and in regulating 
osmotic pressure. PBPs are critical to cell wall biosynthesis and represent the targets of β-lactam 
antibiotics. Inhibition of PBPs leads to abnormalities in the cell such as deformation of structure 
and loss of selective permeability, eventually causing cell lysis. 25, 4, 3 
 




The PBPs in Gram-negative and Gram-positive bacteria have different compositions. In 
Gram-positive bacteria, the peptidoglycan is produced in multiple layers and it expands. On the 
other hand, in Gram-negative bacteria, 50% of its peptidoglycan is recycled and is composed of a 
thin layer.  Different bacteria may have different peptidic sequence, but is usually terminated at 
the D-Ala, D-Ala moiety. 25, 4, 3 
 
The discovery of β-lactams as antibiotics 
The use of antibiotics dates back to the Ancient Egypt, starting with eating garlic—known 
today for its antibacterial properties, and with putting molds on injuries. This concept of an 
organism inhibiting the growth of another organism was not too apparent, but it was discovered 
when Penicillium mold effects were observed. In 1921, Alexander Fleming left culture plates with 
Staphylococcus in his laboratory and left for vacation. When he came back, he discovered 
Penicillium notatum mold in the culture plates, and he observed that the Staphylococcus colonies 
were surrounded by mold were undergoing lysis. Based on his studies, he concluded that mold had 
antibacterial properties. In 1928, Fleming, Dr. Stuart Craddock and Mr. Frederick Ridley purified 
the lytic agent from the Penicillium notatum and called it penicillin (Figure 4), the structure of 
which is characterized by a four-membered β-lactam ring, fused to a five-membered thiazolidine 
ring. This success lead to the use of penicillin as antibiotic in trials in the 1940s penicillin finally 
became available commercially from large scale production laboratories such as fermentation 
laboratories in the U.S. and isolation laboratories from Penicillium chrysogenum in Peoria. After 
the success of penicillin, other classes of β-lactams with different chemical structures were 




Figure 4. General structures of penicillin and cephalosporin.  
Carbapenem Antibiotics 
Carbapenems are a sub-class of β-lactam with a five-membered ring fused to the β-lactam 
ring (Figure 5). The carbapenem structure is similar to penicillin, but with a carbon instead of 
sulfur at the first position, a double bond between C2 and C3, and a C1 β-hydroxyethyl group, 
replacing the C1β-acylamido groups of the penicillin and cephalosporin classes. These structural 
differences render carbapenems poor substrates for many β-lactamases, enzymes that causes β-
lactam hydrolysis. This class of β-lactams plays a critical role in the antibiotic world, where it 
possesses the broadest spectrum of activity. Due to its high effectiveness, it is used for high-risk 
bacterial infections as a “last resort” antibiotic. However, carbapenems have a low oral 
bioavailability, so they are administered intravenously. 39, 40, 44 
 
 


































The Mechanism of Action of Carbapenems 
Like all β-lactam antibiotics, the carbapenem targets are the PBP transpeptidases 
responsible for cross linking peptidoglycan strands during bacterial cell wall biosynthesis.  In the 
case of GN pathogens, the carbapenems must traverse the outer membrane through the water-filled 
porin channels to enter the periplasm, where this cross-linking process occurs.  In the case of GP 
bacteria, however, the cell wall is external, so no such barrier exists.  The carbapenem antibiotics 
form a covalent ester linkage with the active site serine residue of the PBP transpeptidase, resulting 
in the inhibition of formation of the peptidoglycan cross-linkage. This leads to the inhibition of the 
PBP’s ability to catalyze the formation of peptidoglycan (cell wall composition), causing an 
increase in osmotic pressure. As a result, the cell wall weakens, and the cell will burst.  
The term “penicillin-binding-protein” is specifically used for the enzymes that recognize 
the β-lactams. β-lactams inhibit transpeptidation/carboxypeptidation by structurally being similar 
to D-Ala-D-Ala–peptide moiety (Figure 6). The PBP is acylated by the antibiotic (Scheme 1), 
with concomitant opening of the β-lactam ring. The stable acylated PBP can no longer catalyze 
the hydrolysis of the acyl-enzyme intermediate, which causes inactivation. This weakens the 
peptidoglycan, which eventually causes cell death. 8, 32, 
 
 









































The first carbapenem isolated was thienamycin (Figure 7) which demonstrated a potent 
broad-spectrum activity and resistance toward the class A and C β-lactamases common in the 20th 
century. Thienamycin binds to penicillin-binding proteins (PBPs) and is effective towards both 
Gram-negative bacteria (such as Pseudomonas aeruginosa) and Gram-positive bacteria (such as 
Staphylococcus aureus and streptococci). However, thienamycin was considered too unstable for 
commercial development, as it was sensitive to mild bases above pH 8 and nucleophiles. Therefore, 
there was a need for a better carbapenem.32 
 
 
Figure 7. Structure of thienamycin. 
Imipenem  
Imipenem and panipenem (Figure 8) are carbapenems that are potent against both GP and 
GN bacteria. Imipenem, a C2 derivative closely structurally related to thienamycin, became the 
first carbapenem used to treat infections. This carbapenem was better than thienamycin due to its 
stability in mild base. Like thienamycin, it also had stability against β-lactamase and had great 










a DHP inhibitor to protect it from being hydrolyzed by DHP-I. So, the search continued to generate 
a better carbapenem that was not sensitive towards DHP-I. 32 
 
Figure 8. Structure of imipenem and panipenem. 
Meropenem 
Other carbapenem derivatives that were not as sensitive as imipenem towards DHP-I were 
made and found to be more effective against Gram-negative bacteria. It was discovered that a 
methyl group at the C1 position of the β-lactam protects the molecule from being hydrolyzed by 
DHP-I. This type of carbapenem has a broader antibacterial spectrum, better stability, and less 
susceptibility to many β-lactamases mostly due to the methyl group on the C1 position. 
Crystallographic analyses indicated that the hydroxyethyl R2 function group helps the carbapenem 
resist hydrolysis by β-lactamases. Moreover, the trans configuration at C5 and C6 further improves 
stability against β-lactamases, with the hydroxyl group displacing the hydrolytic water. (Figure 
10) The carbapenems with a methyl at C1 included meropenem, ertapenem, biapenem, and 
doripenem (Figure 11). These carbapenems showed broader antimicrobial spectrum due to the 
pyrrolidine moiety. Doripenem showed better potency against P. aeruginosa and A. baumannii, 



















showed potency against the multi drug-resistant (MDR) Mycobacterium tuberculosis when it is 























































































                                  
Figure 11. A. shows a methyl at C1, which reduces susceptibility to DHP-1. B. Shows the 
pyrrolidine ring, which increases stability of the β-lactam. C. shows penicillin to show difference 
between it and carbapenem, where carbapenem has a methyl at C1 position while penicillin has a 
sulfur. D. Shows cephalosporin with sulfur group. E. points out the hydroxyethyl group at R 
configuration and trans configuration at C5 and C6, which increases the β-lactam’s potency. F. 



















































































Bacterial Resistance to Carbapenem 
Bacterial pathogens have several mechanisms to protect themselves against carbapenems. 
For example, Pseudomonas aeruginosa (Gram-negative) can both release β-lactamase into the 
periplasm (location of PBP) and use efflux pumps to export antibiotics. Other bacteria, such as 
streptococci and Staphylococcus aureus (Gram-positive), produce mutated PBPs. 19, 32 
 
β-lactamase 
β-lactamase is an enzyme that hydrolyzes the β-lactam ring (Scheme 2) resulting in the 
opening of the ring and rendering the antibiotic unable to bind to PBP. There are four molecular 
classes of β-lactamases, A, B, C, and D. Each class of β-lactamase has one or more types of β-
lactamase. Class A consists of β-lactamases with varying substrate specificity. For example, it 
contains penicillinases, which attack penicillin. It contains, extended-spectrum β-lactamases, 
which attack penicillin, cephalosporins and monobactams. It also consists of carbapenemases, 
which attack most β-lactams. Class B contains metallo carbapenemases, which attack most β-
lactams. Class C contains expended-spectrum cephalosporinases, which attacks some penams, 
some cephalosporins, and monobactams. Class D contains narrow-spectrum penicillinases, 
extended-spectrum β-lactamases, and carbapenemases, which attack many penams, carbapenems, 
oxacillin, some monobactams and fourth generation cephalosporins.  
Classes A, C, and D are serine β-lactamases that inactivate the β-lactam by hydrolyzing it 
through a nucleophilic attack by serine. On the other hand, Class B β-lactamases use Zn2+ and a 
Zn-complexed hydroxide to hydrolyze the β-lactam. Carbapenemases, which are members of class 
 
 18 
A, B, and D β-lactamases, are considered to be a major player behind carbapenem resistance due 
to their versatile hydrolytic ability. 10, 14, 18, 32 
  
Scheme 2. Hydrolysis of carbapenem by serine-based β-lactamase 
 
 
Class A, C and D 
  
Class A 
Classes A, C and D are active-site-serine β-lactamases, which are grouped according to 
sequence homology.  Until recently, the carbapenem class of antibiotics remained stable to most 
of these enzymes.  Particularly in Class A and Class D, however, the past 20 years has seen the 
evolution of some of these serine β-lactamases into carbapenemases, thereby effectively bestowing 
carbapenem-resistance to the producing species.  One recent class A carbapenemase has a disulfide 
bond (such as KPC2 carbapenemase) that alters the distance between certain amino acids (for 
example, Ser70 and Thr237), which causes the active site length to decrease. As a result, the steric 
hindrance that is made by the hydroxyethyl group on the C6 position (which is a major function 







































carbapenemases hydrolyze imipenem and other carbapenems. Another example includes non-
carbapenemase GES-1, which can turn into a GES-2 carbapenemase only by the substitution of 
Gly170Asn amino acid. In addition, if Gly170 was mutated to Ser, the GES-2 mimics a stronger 
carbapenemase called GES-5, which has a higher rate of acylation for imipenem by 5,000-fold 
than GES-2.  10, 14, 18, 32 
Class D 
Class D β-lactamases have a few OXA carbapenemases types. Acinetobacter baumanni 
strains commonly harbor a class D β-lactamase, which produces resistance against carbapenems. 
The major carbapenemase type in Acinetobacter baumannii is the OXA-23 β-lactamase. This type 
of carbapenemase is a major problem because it has resistance to meropenem, knowing that 
meropenem is a last-resort antibiotic against Acinetobacter baumanni. Class D β-lactamases have 
high structural diversity, which allows them to have high resistance to a broad-spectrum of 
antibiotics. Class D resembles class A β-lactamase where the serine undergoes acylation by the β-
lactam with a lysine residue that promotes the process. In class D, however, the acylation and 
deacylation occur through the N-carboxylated lysine residue. It was suggested that class D β-
lactamases have a hydrophobic tunnel barrier that only allows certain substrates to reach the active 






Class B  
When it comes to class B β-lactamase, it is divided to three suβ-classes; 1, 2, and 3. B2 
(such as CphA) functions when it binds to one Zn+2, while B1 and B3 (metallo-β-lactamases) are 
optimally active when they bind to two Zn2+. The metallo-β-lactamase subclasses function by 
having a Zn2+ ion lower the pKa of a water molecule. The water molecule then generates hydroxide, 
which acts as a nucleophile to attack the carbapenem. The second Zn2+ ion stabilizes the formed 










Figure 12. Subclass B1 and B3 metallo-β-lactamase active sites.32 
 
When it comes to class B2, hydrolysis occurs when the carbapenem bond is cleaved by a 
water molecule nucleophile that is coordinated with His118 and Asp120. Another water molecule 
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(coordinated with Asp120, His263, Cys221 and Zn+2 ) bonds with the carboxylate of the β-lactam 
and donates a proton to the nitrogen in the carbapenem (Scheme 3). 10, 14, 18, 32, 33 
 
 
Scheme 3. Stabilization of the anionic intermediate. 32 
 
Porins 
Outer membrane protein (OMPs), known as porins, allow molecules to pass through the 
outer membrane to the periplasm. There are four types of porins in bacteria—general, specific, 
gated, and efflux porins. Since different types of bacteria have different OMPs, not all 
carbapenems are affected the same way by porins. Specific and gated porins permit entry of 
carbapenems into the cell. These types of porins are present in K. pneumoniae and E. coli. On the 
other hand, efflux pumps force certain carbapenems out of the cell. There are five major families 
of efflux pumps which include the adenosine triphosphate (ATP)-binding cassette (ABC) 
superfamily, the resistance-nodulation-division (RND) family, the small multidrug resistance 
anionic intermediate  
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(SMR) family, the major facilitator superfamily (MFS) family, and the multidrug and toxic 
compound extrusion (MATE) family. Multidrug efflux pumps are present in all bacteria, and many 
have more than one type of efflux pump (such as Mycobacterium tuberculosis). Moreover, some 
types of bacteria have low efflux expressions while some have higher efflux expression, and 
expression can be either be induced (transiently) or due to mutations (constitutively). A single 
efflux pump can extrude multiple antibiotics; thus, using efflux pump inhibitors can eventually 
cause an increase in a bacteria’s susceptibility to several antibiotics. Another way to overcome the 
efflux pump mechanism is by modifying the β-lactam’s functional groups in order to reduce its 
affinity to the efflux pump, depending on the targeted bacteria and their efflux pump affinities. 4,13, 
31, 38  
 
PBP Mutations 
As mentioned, b-lactams bind to the PBP by mimicking D-Ala, D-Ala moiety (Figure 13). 
However, certain bacterial pathogens can achieve resistance to β-lactam antibiotics by mutating 

























When it comes to Mycobacterium abscessus (Mab) and Mycobacterium tuberculosis (Mtb), 
the majority of peptidoglycan linkages are between the third residue (3 3) of two adjacent 
peptide stems. This is formed by L,D-transpeptidases (Ldt), which is a class of cysteine 
transpeptidase, and is not recognized by most classes of β-lactam antibiotics. The glycan strand is 
composed of a polymer of alternating B(1-4) linked N-acetyglucosamine (NAG) and N-
glycolymuramic acid (NGM) with L-Ala-D-iGlu- meso-2,6-diaminopimelate[DAP]-D-Ala-D-Ala 
stem peptide attached though a lactic acid moiety. The bacteria’s structure gets its strength and 
long-term survival from the mesh formed by the cross linkage of the peptide stem (missing a D-
Ala) with a nearby stem peptide from a different glycan strand. This process is catalyzed by PBP 
and Ldt to form both linkages of (4  3) and (33) (Figure 14), with (33) cross links being 




Figure 14. Difference between 4  3 linkage, which is shown at the top, and 3  3 linkage, 
































































































Mtb, which causes tuberculosis (TB), is a multidrug-resistant (MDR) and extensively drug-
resistant (XDR) pathogen. Mtb has been spreading at a high rate. According to Center for Disease 
Control and Prevention (CDC), TB is one of the top 10 causes of death. In 2017, TB caused an 
estimated 1.3 million deaths among HIV-negative people and 300,000 deaths among HIV-positive 
people. 10 million people developed TB in 2017. Approximately 1.7 billion people are estimated 
to have latent TB, which means 23% of the world’s population is at risk of developing active TB.  
TB treatment is composed of a combination of chemotherapy for two months followed by 
four months of isoniazid and rifamycin. This extended duration of treatment makes it hard for 
patients to comply. Although this noncompliance is a factor of the spreading of the disease, the 
high resistance of Mtb to β-lactam antibiotics is a major problem. This resistance is caused by the 
chromosomally encoded gene of class A Ambler β-lactamase (BlaC), which is a broad-spectrum 
enzyme that hydrolyzes all class of β-lactams and which can be inactivated by the β-lactamase 
inhibitor, clavulanic acid. In a study by Hugonnet et al, they showed that a combination of 
meropenem and clavulanate were effective against 13 strains of Mtb due to poor hydrolyzation of 








































specifically type 2 (LdtMt2). The 33 cross-link is between the carboxy terminus of a DAP on the 
peptide stem with NH2 of a DAP on another stem (Figure 14). Carbapenems were reported to 
target this type of enzyme (Scheme 4). 24 More specifically, the combination of meropenem-
clavulanic acid have been proven to stop the formation of transpeptidase and inactivate β-
lactamase. 11, 13, 16  
Mab Resistance 
Mycobacterium abscessus (Mab) is a rapidly growing nontuberculous mycobacterium 
(NTM), which is responsible for as high as 80% of NTM pulmonary infections. It also causes skin 
and soft-tissue infections, central nervous system infections, bacteremia, and ocular infections. 
Mab is highly resistant to antibacterial agents and causes dangerous diseases such as respiratory 
disorders and soft tissue disorders. Mab is a major problem because not only are they resistant 
against various antibiotics, but they are also resistant to disinfectants. Also, Mab causes a lot of 
pulmonary diseases, which are very hard to cure and require a combination of antibiotics a 
macrolide and intravenous agents for 2 weeks to 12 months, depending on the type of infection or 
disease. For example, pulmonary diseases are treated with a macrolide in combination with other 
antibiotics and central nervous system infections are treated with clarithromycin combined with 
other antibiotic and both have a 12-month recommended treatment duration. Skin and soft tissue 
infections are treated with a macrolide in combination with imipenem and other antimicrobial 
therapy for a minimum of 4 months. 34 In 1990a, the combination clarithromycin, amikacin, and 
imipenem (or cefoxitin) were reported as the best multidrug therapy. 7, 8, 34, 40 
Imipenem and cefoxitin have shown MICs of 16 and 32 mg/L respectively, against Mab. 
Mab is highly resistant to other β-lactams. Mab has hydrophilic porins that potentially allow β-
lactams into the cell. However, the major challenges when facing Mab is its low permeability and 
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β-lactamase, which make it resistant to antibiotics. It has a gene encoding an Amber class A β-
lactamase (BlaMab), which is inactivated via avibactam via reversible formation of a covalent 
adduct.  
Acinetobacter baumannii Resistance 
Acinetobacter baumannii is an MDR pleomorphic aerobic Gram-negative coccobacillus, 
and a major pathogen, of increasing clinical concern, causing nosocomial infections.  It is one of 
the most successful types of pathogens that are spread in hospitals. For example, in 2018, 180 
strains of Acinetobacter baumannii out of 1259 GN bacilli isolates were identified in 13 hospitals. 
The mortality rate of inpatients with Acinetobacter baumannii is 26-55%.  
Acinetobacter baumannii is responsible for many soft tissue infections, such as skin 
infections and urinary tract infections. It is one of the most successful types of pathogens in 
escaping antimicrobial antibiotics. It degrades the antibiotics through enzymes (β-lactamase), 
target modification, efflux pump and permeability defects.22 All four types of β-lactamases (A, B, 
C and D) were identified in Acinetobacter baumannii. A number of class A β-lactamases 
(including carbapenemases) have been identified in Acinetobacter baumannii, which are generally 
inhibited by clavulanate.  These enzymes hydrolyze penicillin and cephalosporins. A variety of 
class B β-lactamases have also been identified, which hydrolyze carbapenems. A number of class 
C β-lactamases have also been identified, including cephalosporinases. Finally, class D β-
lactamases, including more than 400 OXA-type (oxacillinases- type) have been identified, and 
many have carbapenemase activity, such as OXA-23. Carbapenems are used to treat Acinetobacter 
baumannii are imipenem, meropenem and doripenem. Carbapenems are usually combined with a 






Synthetic Strategy and Discussion 
There are many challenges that need to be taken into consideration when synthesizing 
carbapenem antibiotics. The structure of new antibiotics should have affinity to PBPs but not for 
β-lactamases. It must be able to penetrate the GN outer membrane efficiently and not be pumped 
out by efflux pumps. Meropenem is one of the most successful types of carbapenems. 
Carbapenems are a successful class of β-lactam due to the many special features in the structure. 
Carbapenems are different from penicillin in having a carbon in place of sulfur at the C1 position, 
a double bond between C2 and C3, special C2 side chains, and a C6 hydroxyethyl side chain. Each 
functional group has a role in improving the potency of the drug. The C6 hydroxyethyl group is 
important to activity as it aids in resistance to hydrolysis by β-lactamases, and its stereochemistry 
is very important to the carbapenem’s activity. As mentioned above, the hydroxyethyl group 
causes steric hindrance that is important in inhibiting class A β-lactamase. The stereochemistry of 
the functional groups of the β-lactam are important as well. For example, positions C5 and C6 
show an increase in stability against β-lactamase in trans configuration, and a hydroxyl group at 
C8 shows better potency in the R configuration. 17, 22, 39 
The methyl group at the C1 position of the carbapenem, meropenem, improves the stability 
of the antibiotic against β-lactamases and protection against DHP-I hydrolysis, which improves 
the in vivo half-life of the antibiotic. The addition of a methyl at C1 showed broader antimicrobial 
activity. The basicity of the nitrogen group on the side chains helps the antibiotic penetrate more 









Modification at C5 
The C5 position has not been investigated. There is only one paper about the C5 position 
written in 1989 by Onoue, Hiroshi, and Yukitoshi Narukawa. Therefore, we decided to evaluate 
C5 substituted carbapenems for better potency against certain pathogens. Therefore, it was decided 
to make a carbapenem with a methyl at the C5 position and a carbapenem with an ethyl at the C5 
position in order to add hydrophobicity to the antibiotic and fill the small hydrophobic pockets 

















Figure 16. Shows a part of Mtb binding with a meropenem analogue acyl-enzyme binding to 
Cys354 and His352. It shows the hydrophobic pockets, Met303 and Val322, that would 
potentially bind to a meropenem analogue with methyl at the C5 position.  
 The molecule needs to be small in order to pass through the porins of the bacteria. It is 
also preferable to have the nitrogen group in the C2 side chain, as it gains a positive charge, and 
goes through the hydrophilic porins of the bacteria more efficiently. The hydrophilic porins are 
intended to uptake positively charged amino acids.  
Meropenem, a commercial antibiotic, is one of the most successful antibiotics because of 
its side chain (at the C2 position) ability to bind to several PBPs and penetrate through the OM. 
The first antibiotics synthesized in this research were made with a meropenem side chain at the C2 
position (10, 21), knowing that meropenem showed activity against Mtb when combined with 
clavulanic acid.48   The second antibiotics were made with an ethyl sulfur side chain, which is a 




Scheme 5. Synthesis of antibiotic 10, 13, 21 and 24. 
a) THF,1) (CuI)4.3[(CH3)2S], -60 
oC, 2) CH3MgI if R = CH3, CH2CH3MgI if R = CH2CH3, 10 
oC. 
b) EtOAc, NaOAc, AcOH, RuCl3, O2, MeCHO, 12-15 
oC. c) CH2Cl2, Compound 5, ZnCl2, 42 
oC. 
d) CH3CN, HF. e) EtOAc, Rh2(OAc)4, 60 



















R = CH3, Antibiotic 10
R = CH2CH3, Antibiotic 21
R = CH3, Antibiotic  13
































































R =  CH3, Antibiotic 10 
R = CH2CH3 Antibiotic 21
R = CH3, Antibiotic 13
R = CH2CH3 24
h
j
R = CH3 3
R = CH2CH3 15
R = CH3 4
R = CH2CH3 16
R = CH3, 6
R = CHCH3, 17
R = CH3, 7
R = CH2CH3 18 R = CH3 8
R = CH2CH3 19
R = CH3 11
R = CH2CH3 22
R = CH3 9
R = CH2CH3 20
R = CH3 12




(2S,4S)-2-(dimethylcarbamoyl)-4-mercapto-1-pyrrolidinecarboxylate, -35 oC. g) CH3CN, DIPEA, 
-35 oC. h) EtOAc, 0.3 M pH = 6 phosphate buffer, Pd/C, H2. i) THF, CH3CH2SH -78 
oC, n-BuLi, 
j) EtOAc, 0.3 M pH = 6 phosphate buffer, Pd/C, H2.  
The carbapenem was synthesized by starting with commercial azetidinone with an acetoxy 
group at the C4 position (47). Several synthetic methods of the generation of the first step (3) were 
evaluated. The first method included methyl zinc iodide (Scheme 6), which was made by reacting 
methyl iodide with Zn in CH2Cl2. However, the reaction did not succeed. So, it was repeated, but 
in the presence of ZnCl2 in order to coordinate with the acetate oxygen and make it a better leaving 
group. However, the reaction failed again. Then, it was decided to repeat the reaction, but in the 
presence of copper iodide dimethyl sulfide complex. Once again, the reaction did not yield any 
product. 
Consequently, we decided to use a different method. So, a Gilman reagent was prepared 
by reacting methyl iodide with lithium metal in Et2O to yield methyllithium (Scheme 7), and a 
copper iodide dimethyl sulfide complex was prepared with it at -60 oC. Then, the mixture was 
treated with the commercial azetidinone (47). However, yield was very low (2% yield). After 
repeating the experiment six times with varying the temperature, it was decided to use another 
method.  
 













Scheme 7. Synthesis of compound 3 using methyllithium. 
Since we desired to avoid reactive organolithium reagent and to increase the yield, a 
Grignard reagent was employed to synthesize methyl magnesium iodide by using methyl iodide 
and magnesium turnings in the presence of a few iodine crystals. In the case of synthesizing an 
ethyl functional group at the C5 position (15), iodoethane was used in place of iodomethane. Then 
copper iodide dimethyl sulfide complex was prepared in anhyd. THF at rt, the reaction 
subsequently cooled to -60 oC, treated with methyl magnesium iodide in Et2O, warmed to -20 for 
10 min, then cooled back to -60 oC, treated with azetidinone (47), and warmed to room temperature. 
The magnesium dimethyl cuprate served as a nucleophile and replace the acetoxy group with a 
methyl group (3) in a reasonable yield (83%).  
Acetoxylation of 3 and 15 was then performed by adding activated ruthenium trichloride 
to catalyze the oxidation with O2 and freshly twice distilled acetaldehyde at 12-15 
oC to yield the 
intermediate, compound 4, 16. Prior to the reaction, it was critical for the ruthenium trichloride to 
be heated using a flame while it was on the high vacuum until the catalyst turned into fine powder 
(approximately 5-10 min of the rb flask containing the RuCl3 in the Bunsen burner flame at 0.1 
mm pressure). The heating of the catalyst activates it and removes the water to generate anhydrous 
RuCl3. The activation does not succeed if a heating-gun was used, so it was important to use a 












species (49) as shown in Scheme 8.  There are two pathways to this reaction. The first pathway 
includes acetaldehyde reaction with the molecular oxygen to yield peracetic acid. The peracetic 
acid then reacts with RuIII to yield the oxoruthenium species 49. The second possible pathway 
includes the formation of metalacyclic intermediate (48). After protonylysis, the reaction give 
acetic acid and oxoruthenium 49 as shown in Scheme 8.51 
Acetaldehyde had to be freshly distilled twice before each reaction in order for the reaction 
to succeed. The distillation remove water from the acetaldehyde and any of the formed polymers 
in the container. It was hypothesized that water was extremely damaging to the reaction. If water 
enters the flask, it might act as a nucleophile and open the β-lactam ring (52) as shown in Scheme 
9. Therefore, a few reagents were used to try to minimize the water in the reaction (shown in Table 
1) such as MgSO4 and ground molecular sieves (4Å), but the reagent did not improve the results. 
It was also very important to add all the acetaldehyde at once in the beginning of the reaction. If 
acetaldehyde is added in aliquots, side product increases. The possible side product is shown in 
Scheme 9. 



































Scheme 9. Hydrolysis of compound 4 by water 
 
Increasing the oxygen pressure also improved yield. The reaction was run with an oxygen 
balloon only at first, and the septum of the reaction was opened to obtain NMR samples. It was 
observed that the reaction needed an increase in pressure, and that it was extremely sensitive to 
moisture. Therefore, 12 psi O2 pressure was applied, the vessel was closed at all times, and samples 
were taken out for monitor using a syringe. If oxygen pressure was lost, the reaction ended. The 
syntheses of compound 4 (with methyl at C5) and compound 15 (with ethyl at C5) were repeated 
104 times, varying the temperature, reagents, and the equivalents of the reagents, and it was shown 
that the optimized results used 11 mol % of activated RuCl3, 0.27 equivalence of NaOAc, 9.6 
equivalences of acetic acid, 13.4 equivalences of acetaldehyde, and 12 psi dry O2 pressure at 16-
18 °C and increased amount of EtOAc. (Table 1).  
The product was then reacted with the TBS enol ether of p-nitrobenzyl 2-diazoacetoacetate 
(5) in the presence of ZnCl2 to coordinate with the acetate (53), making the acetate a better leaving 
group. in order to provide the structure for the five-membered ring next to the β-lactam ring 
(Scheme 10). This reaction was also performed multiple times (32 times) with multiple variations 
(Table 2). Therefore, silica gel was used as a reagent to tautomerize the product to the desired 



























decided to use ZnCl2 in Et2O, which improved results. The variations of reagents and conditions 
are shown in Table 2.  
Scheme 10. synthesis of compound 6 and 7. 
The product (6) was then treated with 1 mL of HF in order to remove the TBS protecting 
group (7) as shown in Scheme 10. The β-lactam was then treated with catalytic rhodium acetate 
at 68 °C to cyclize the compound 7. The diazo functional produced N2 gas and generated a carbene 
(54). The generated rhodium carbenoid (56) inserts into the N-H group, forming a bicyclic 

























































Scheme 11. Synthesis of compound 8 
Product 8 was then treated with diphenyl phosphoryl chloride and diisopropylethylamine 
at -35 oC. The diisopropylethylamine removed the acidic proton at C3, generating an enolate anion 
(58), which is phosphorylated at the oxygen (11) as shown in Scheme 12. The phosphate then acts 
as a good leaving group for the next reaction (60). The thiol side chain was then added with 
diisopropylethylamine to the intermediate (9, 12) (Scheme 12). After purification, the compound 
is hydrogenated at 55 psi in EtOAc and phosphate buffer to remove the p-nitrobenzyl protecting 























































































































1 0.0665  0.27  9.6  13.4  30 mL 3 rt  0 
2 0.0723  0.27  9.6  13.4  30 mL 3 rt MgSO4 0 
 0.0723  0.27  9.6  13.4 30 mL 3 rt Molecula
r sieves  
0 
3 0.0723  0.27  9.6  13.4  30 mL 3 35  0 
4 0.0723  0.27  9.6  13.4  30 mL 3 0  0 
5 0.33  0.54  9.6  13.4  30 mL 3 rt MgSO4 0 
9 0 0.27  9.6  13.4  30 mL 3 rt Ru(acac)3 0 
6 0.33  0.27  9.6  13.4  30 mL 3 55  0 
7 0.33  0.27  9,6  13.4  30 mL 3 rt Molecul-
ar sieves  
0 




9 0.33  0.27  0 13.4   30 mL 3 rt Ac2O 0 
Ru(acac)
3
: Ruthenium(III) acetylacetonate 
AgOTf: Silver trifluoromethanesulfonate 
Ac
2
O: Acetic anhydride  























10 0.0723  0.27  9.6  13.4  30 mL 3 35  10% 
11 0.0723  0.27  9.6  13.4  30 mL 3 40  10% 
12 0 0.27  9.6  13.4  30 mL 3 rt 0.074 eq 
Ru(acac)3 
0 
13 0.0723  0.27  9.6  13.4  30 mL 3 0  6% 
14 0.0723  0.27  9.6  13.4  30 mL 3 rt AgOAc 0 
15 0.33  0.27  9.6  0 30 mL 3 rt PAA 0 
16 0.43  0.27  9.6  13.4  30 mL 3 rt  25% 
17 0.33  0.27  9.6  13.4  15 mL 3 rt PAA 0 
18 0 0.27  9.6  13.4  15 mL 3 rt 0.24 eq of 
5% Ru/C 
+ 
1.5 eq of 
MCPBA 
0 
19 0.66  0.27  9.6  13.4  15 mL 3 rt AgOTf 0 
Ru(acac)
3
: Ruthenium(III) acetylacetonate 
AgOAc: silver acetate 
PAA: Peracetic acid  
AgOTf: Silver trifluoromethanesulfonate 







Table 1.3. Compound 4. RuCl3 heated using a Bunsen burner under high vacuum. Freshly twice 

















20 0.33  0.27  9.6  13.4  15 mL 12 0  0 
21 0.33  0.27  9.6  13.4  15 mL 12 15 9 eq 
HCOOH 
0 
22 0.33  0.27  9.6  17.9 eq 15 mL 12 0  33% 
23 0.33  0.27  9.6  13.4  15 mL 12 0 0.0113 





24 0.33  0.90  9.6  13.4  15mL 12 0  33% 
25 0.33  0.27  9.6 13.4  15 mL 12 18  66% 
26 0.11  0.27  9.6  13.4 56 mL 12 16  95% 
HCOOH: formic acid  





Table 2.1 Variation of reagents for compound 6 using ZnCl2 salt. 





1 2 eq 0.5 eq 2 mL rt  0% 
2 1 eq 0.5 eq 4 mL 36  5% 
3 2.5 eq 1 eq 1 mL 36  5% 
4 1.5 eq 0 1 mL 36 0.5 eq 
ZnBr2 
5% 
5 1.5 eq 0 1 mL 36 0.5 eq 
ZnI2 
0% 
6 1.5 eq 0 4 mL 40 0.5 eq 
ZnBr2 
5% 
Table 2.2 Variation of reagents for compound 6 using 1 M ZnCl2 in Et2O. 







7 1.5 eq 0.5 eq 2 mL 35  30% 
8 2 eq 0.5 eq 2 mL 35  30% 
9 3 eq 0.5 eq 2 mL 35  10% 
10 4 eq 1 eq 2 mL 35  5% 
11 3.5 eq 0.5 eq 0 70 2 mL 
toluene 
30% 









Results of C5 Substituted Carbapenems 
Antibiotics 10, 13, 21 and 24 were all designed against Mtb and Mab, which have shown 
that they need a hydrophobic functionality at the C5 position according to previous results. The 
antibiotic was microbiologically evaluated against Mtb at UCF, in the laboratory of Dr. Kyle Rohde. 
Antibiotic 10 showed that it was more than twice as active as the best commercial antibiotic, 
meropenem, against Mtb and more than four times as potent against Mab. The MIC (µM) of 
antibiotic 10 against Mtb is 0.4 and 1.2 against Mab, whereas meropenem show MIC of 1.8 against 
Mtb and 15.0 against Mab as shown in Table 3.0. Antibiotic 10 and meropenem were evaluated 
with and without an inhibitor, and in both cases antibiotic 10 showed lower MIC as shown in 
Figure 17. All other antibiotics, 13, 21, and 24, did not generally show better activity than 
meropenem. Antibiotic 13 showed better potency against Mtb than the commercial meropenem as 
shown in Table 3.0.  
Table 3.0. MICs of antibiotics 10, 13, 21, and 24 against Mtb with and without clavulanic acid 
and Mab with and without avibactam.  
 Mtb MIC (µM) Mab MIC (µM) 
Antibiotic No CLA CLA No AVA AVA 
Meropenem 1.8 0.9 15.0 12.6 
10 0.4 0.2 1.2 1.1 
13 1.0 0.3 22.7 14.3 
21 3.4 3.0 33.1 75.7 
24 24.3 16.8 - - 
CLA = clauvulanic acid 




                
  
                    
 
 
Figure 17. A. shows structure of commercial meropenem, 10, 13, 21, and 24. B. Progress curve 
for inhibition of Mtb and Mab, with and without β-lactamase inhibitors, clavulanic acid or 
avibactam, respectively. 
 
Antibiotics 10, 13, 21, and 24 were also sent to Notre Dame labs to be evaluated against 
Acinetobacter baumannii (A. baumannii) with OXA-23 β-lactamase. Antibiotic 10 and antibiotic 
21 displayed superior activity against Acinetobacter baumannii. Both antibiotics have a 
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C5 position while antibiotic 21 has an ethyl group at the C5 position. Since both compounds 
showed activity against OXA-23 producing A. baumannii, the compounds were also tested as 
inhibitors of the OXA-23 -lactamase.The compounds were shown to increase meropenem 
potency against Acinetobacter baumannii producing OXA-23 by 2024 fold indicating that it is an 
inhibitor of the OXA-23 carbapenemase. OXA-23 is a class D β-lactamase that produces resistance 
to carbapenems, as described in the introduction. Antibiotics with a C2 thioethyl side chain did not 
show potency against Acinetobacter baumannii as shown in Tables 3.1, 3.2, and 3.3. All 
antibiotics showed activity against E col.i (genetic type JM83), especially 10. Antibiotic 10 
showed an MIC value of 0.5, however, commercial meropenem has an MIC value of 0.030 against 
E col.i JM83.  
 
Table 3.1.  MICs of compounds 10, 13, 21 and 24 against E. coli JM83 background with and 
without the OXA-23 β-lactamase.  
  
Compound # JM83 





Meropenem 0.030 - - 
10 0.5, 0.5, 0.5, 0.5 0.5, 0.5 0 
13 2, 2, 2 4, 4 2 
21 4(8), 8(4), 8 4(8), 8 0 
24 32 >64 - 
 
 
Table 3.2. MICs of meropenem against A. baumannii CIP 70.10 producing OXA-23 in the 
presence of compounds 10, 13, 21 and 24 treated as inhibitors.  
                                              





Meropenem 64, 64, 64 - 
10 ≤1, ≤0.031 ≥2048 
13 2, 4 16-32 
21 ≤1, ≤0.031 ≥2048 
24 32, 64 0-2 
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Table 3.3. MICs of compounds 10, 13, 21 and 24 against A. baumannii CIP 70.10 background 
with and without the OXA 23 β-lactamase.  
 
Compound # CIP 70.10 




Meropenem 0.5, 0.5 64, 32/64 
10 0.5, 0.5, 0.5 4, 4 
13 8, 8, 8 8, 8 
21 2, 2, 2 4, 4 
24 >32 >64 
 
Table 3.4. MICs of meropenem against A. baumannii CIP 70.10 producing the OXA-23 β-
lactamase in the presence of compounds 10 and 21 treated as inhibitors.  
  




MIC (µg/ml) of 
meropenem 
Fold change 
10 0.5 32(64) 0-2 
1 32, 16/32 0-4 
2 16 2-4 
4 ≤0.031, ≤0.002 ≥16000 
21 0.5 32 0-2 
1 32, 32 0-2 
2 16 2-4 
4 ≤0.031, ≤0.002 ≥16000 






C5 AND C1 SUBSTITUTIONS 
 
 
Modification at C5 and C1 Simultaneously 
It was very clear that methyl or ethyl at the C5 position improves the observed MIC values 
against Mtb, Mab and Acinetobacter baumannii. On the other hand, 1 β-methylcarbapenem also 
exhibit potent antibacterial activity. Meropenem exhibit a broad spectrum of antibacterial activity 
against Gram-negative, Gram-positive bacteria, and mycobacteria. As shown in Table 2, 
antibiotics 10 and 21 were superior against Acinetobacter baumannii when combined with 
meropenem. Therefore, our lab desired to generate a carbapenem with methyl at both C1 and C5 
position. The desired scheme for this compound is shown on Scheme 13. Many different methods 




Scheme 13. Anticipated scheme for adding a methyl group on C5 and C1 positions on β-lactam 
using chiral oxazolidine. 
 
The synthesis of this carbapenem started by treating compound 4 with chiral oxazolidine 
(61), which can be effectively used as a chiral auxiliary for a stereoselective reaction. Compound 
4 was treated with compound 61 at -35 oC using titanium tetrachloride in the presence of an organic 
base.  The titanium tetrachloride forms an enolate on the chiral oxazolidine to couple with the β-
lactam.  
In order to avoid TiCl4, oxazolidine was treated with tert-butyldimethylsilyl 













































































CH2Cl2, cooled to -78 
oC, treated with compound 4 and then treated with ZnCl2. However, the 
desired product shown on Scheme 14 was not obtained. Three undesired products were obtained 
according to the NMR. The first two products were ring-open products of the β-lactam, and the 
third product was a coupling of two β-lactams. The N-H can act as a nucleophile by attacking the 
β-lactam intermediate to yield the product of two β-lactams attached to each other as shown in 
Scheme 15. This reaction was also attempted with oxazolidine with a bromine (70 shown in Figure 
18) using TiCl4, however, undesired product 4 shown in Scheme 15 was obtained according to the 
1H NMR.  
 


































































































Scheme 15. mechanism of obtained undesired products instead of added methyl to C1 position.  
 
 
Since the oxazolidine methods were unsuccessful, we decided to approach the product 
differently by using methyl 3-oxovalerate (73). First, the reaction was attempted with commercial 
azetidione (47). The first method included treating the methyl 3-oxovalerate with NaH in order to 
get a dianion methyl 3-oxovalerate (74) and couple it with compound 4 using ZnCl2 in the presence 
of n-butyllithium. However, the NMR shows that the methyl 3-oxovalerate was added to the β-
lactam through the anion in between the carbonyls, which yielded the undesired product 76 shown 
in Scheme 16. Therefore, another approach was taken by converting methyl 3-oxovalerate to 
methyl 2-diazo-3-oxovalerate, treating it with TMS-OTf (44), then coupling it with compound 4 





















































Scheme 17. Anticipated antibiotic scheme with methyl at C5 and C1 position using methyl 3-
oxovalerate instead of chiral oxazolidine. 
 
 
Therefore, it was decided to take methyl propionylacetate, add diazo group and convert it 
to the enolate form using TMS-OTf (44) in the presence of a base. Then, it was coupled with the 











































































































































propionylacetate, compound 4 was tested using the same conditions as shown in Scheme 17. The 
synthesis started by adding PNB protecting group to methyl propionylacetate (73) by mixing them 
together at 170 oC. The PNB alcohol attacks the carbonyl that belongs to the ester, and the 
methanol is distilled out of the system (78). After column purification, the product 42 was taken 
into CH2Cl2 and triethylamine was added to remove the proton between the carbonyls to form an 
enolate (79). The double bond of the enolate is reacted with methanesulfonylazide, transferring a 
diazo group (80) as shown in Scheme 18. A TMS group is then attached to the carbonyl to prepare 
the compound 44 to be coupled with compound 4. Compound 4 is then taken with the TMS enol 
ether (44) and ZnCl2. The ZnCl2 forms a bond with the acetate, which allows it to leave form the 
β-lactam intermediate as shown in previous reaction of Scheme 11. The TMS enol ether is then 
coupled with the β-lactam to yield 45 R and 45 S as shown in Scheme 18.  
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Scheme 18. Adding a methyl at the C1 position to β-lactam with methyl at the C5 position 
 
The diastereomers mixture 45 R and 45 S was treated with HF to remove the TBS group. 
The next steps involve treating the β-lactam with catalytic rhodium acetate at 68 °C to cyclize the 
compound 66. The product would then be treated with diphenyl phosphoryl chloride and 
diisopropylethylamine at -35 (67). The thiol side chain would then be added with 
diisopropylethylamine to form the intermediate 68 shown in Scheme 18, which would then 
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protecting group and produce the anticipated antibiotic 69 shown in Scheme 18. This scheme 







Modification of the C2 Position 
The position at C2 is very important to carbapenem antibiotics. Most β-carbapenems have 
a sulfur linked to a basic amino group at the C2 position to produce porin-mediated transport across 
the OM. Although primary amines decrease the stability of a β-lactam due to the ability of the of 
primary amine to act as a nucleophile and attack the -lactam carbonyl group, like the case of 
thienamycin, the basicity of this amine functionality increases the antibiotic activity. Therefore, 
our lab attempted to synthesize an antibiotic with amino group directly bonded at the C2 position 
as shown in Scheme 19.  
 

































































 a) CH2Cl2, Compound 5, ZnCl2, 48 
oC. b) CH3CN, HF. c) EtOAc, Rh2(OAc)4, 60 
oC. d) CH3CN, 
(PhO)2P(O)Cl, DIPEA, 0 
oC. e) EtOAc, 18-crown 6, KN3. f) THF, Et3N, H2S, 0 
oC. g) EtOAc, 
pH = 6 NaH2PO4 (0.3 M) buffer, Pd/C, H2.  
 
It was decided to make the antibiotic with a primary amine at C2 and evaluate it against 
21st century pathogens. If it showed potency, the same compound would be synthesized with a 
methyl group at C5 to add stability to the structure and make it a potential antibiotic against Mtb. 
The synthesis of the amine compound 30 was successful (Scheme 19), but the deprotection of the 
p- nitrobenzyl by hydrogenolysis to yield antibiotic 31 was never successful. Different methods to 
deprotect compound 30 were used but were unsuccessful. After observing the instability of the 
amine compound, it was decided to acylate it in order to add stability through the resonance 
between the nitrogen and the carbonyl. However, the acylation of the amine was also unsuccessful 
with different methods described in Scheme 20.  
The carbapenem was synthesized by starting with commercial azetidinone with the acetoxy 
group at C4 (47). The product was then coupled with TBS enol ether p-nitrobenzyl ester (5) in 
order to provide the structure for the five-membered ring next to the β-lactam ring (25). The 
product was then treated with 1 mL of HF in order to remove the TBS protecting group (26). The 
β-lactam was then treated with rhodium acetate at 68 °C to cyclize the compound (27). The diazo 
functional group generated N2 gas and generated a carbene. The generated rhodium carbenoid 
formed the ring closure of the five-membered ring (28). The product was then treated with 
diisopropylethylamine at -35 oC. The base and diphenyl phosphoryl chloride converted the ketone 
to the enol phosphate (28), which is a good leaving group for the next reaction. The product was 
then reacted with potassium azide in the presence of 18-crown-6 in order to for the aizde to displace 
the phosphate (29) as shown in Scheme 19.  The 18-crown-6 complexes the potassium into the 
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solution allowing the azide to couple with the compound. The azide β-lactam was then dissolved 
in anhyd THF, treated with triethylamine, and hydrogen sulfide was bubbled through the flask at 
0 oC for a few minutes to reduce the azide to the amine (30). The product was then hydrogenated 
at 55 psi in EtOAc and phosphate buffer solution (pH 6) to remove the p-nitrobenzyl protecting 
group (31), however, this step failed despite multiple attempts. Knowing that amines are very 
sensitive, ethanol was substituted in the last step with 1 equiv of NaHCO3 in DI water and THF. 
However, this attempt was also unsuccessful.  
Since carbapenem-derived amines are very sensitive, I attempted to acylate compound 30 
to add stability through the resonance between the carbonyl and nitrogen. It was thought that the 
acylated nitrogen would add some chemical stability and allow the compound to go through 
hydrogenolysis without decomposition. This reaction was carried out by taking the azide β-lactam 
(compound 30) in dichloromethane. The flask was charged with triphenylphosphine to convert the 
azide to amine through the Staudinger reaction, which is a mild reduction. Triphenylphosphine 
reacts with the azide to generate a phosphazide as shown in Scheme 20. Iminophosphorane is 
formed (80) as a part of the intermediate as shown in Scheme 20, and N2 is generated (81). A 
proton source is provided by the work up of the reaction for the nitrogen to form an amine, and a 
stable phosphine oxide is formed as a side product. However, this reaction failed. It was 
hypothesized that acetyl chloride might have been too strong of an acylating reagent, therefore, it 
was replaced with acetic anhydride. However, the reaction still did not show any product formation. 
Then, the amine β-lactam (compound 32) was treated with acetic anhydride in attempt to acylate 
































Scheme 20. Method A) Reacting compound 29 with triphenylphospine then acetylchloride in 
method 1 and acetic acid in method 2 in attempt to yield acylated amine β-lactam. Method B) 
reacting compund 29 with hydrogen sulfide to yeild compund 30, and then reacting compound 
30 in attemt to yield acylated amine.  
 
Realizing that acetic acid was not a suitable reagent for this reaction, the azide compound 
was dissolved in dichloromethane and treated with thioacetic acid in the presence of lutidine 
(Scheme 21). The lutidine deprotonates thioacetic acid (83) to allow it to react with the azide to 
form a thiotriazoline as an intermediate (84) as shown in Scheme 21, and then the nitrogen is 





























































































Scheme 21. Attempt of acylating compound 30 using thioacetic acid. 
The acylation of the azide carbapenem and compound 30 were attempted using several 
methods Table 4, however, all methods failed. Acetyl chloride along with PPh3, acetyl chloride 
with lutidine and H2S, and acetyl chloride with triethylamine and H2S have all failed. Neither did 
exchanging acetyl chloride with acetic anhydride in all three different methods not using thioacetic 
acid help the reaction succeed.  It was concluded that the amine compound was too unstable to be 































































H2S THF 0 
2 1 eq - 1.9 eq Acetyl 
Chloride 
- 1.4 eq 
PPh3 
CH2Cl2 0 
3 1 eq - 0.6 eq Acetyl 
Chloride 
- 0.8 eq 
PPh3 
CDCl3 0 
4 1 eq - 0.6 eq Acetic 
anhydride 
- 0.8 eq 
PPh3 
CDCl3 0 




H2S CH2Cl2 0 




- MeOH 0 




- CH2Cl2 0 
8 1 eq - 0.8 eq Acetyl 
Chloride 






During this research, I discovered that an amine group directly bonded to the C2 position 
reduces the stability of the carbapenem, making it hard to produce antibiotics with amine at C2. 
Also. During this research I was able to optimize reaction conditions for compounds 3, 4, 15 and 
16, which now permits large productions. I generated compounds that are active against Mtb, Mab 
and A. bumannii, and stable in the presence of OXA-23 -lactamase. I was able to synthesize an 
antibiotic that is better than the commercial antibiotic, meropenem, against Mtb and Mab. Also, the 
synthesized antibiotics worked as inhibitors against A. bumannii in the presence of OXA-23 -
lactamase. Antibiotics were combined with meropenem and increased its potency by more than 








Methylmagnesium iodide (1). A dry 500 mL 3-necked round-bottom flask (w/stir bar) with a 
reflux condenser was charged with magnesium turnings (30.5 g, 1.26 mol, 1.5 eq) in 200 mL of 
anhyd Et2O and a catalytic amount of iodine crystals were added. A solution of methyl iodide 
(118.6 g, 52 mL, 0.835 mmol) in 50 mL of anhyd Et2O was then added to the solution dropwise at 
a rate as to maintain gentle reflux. The reaction was allowed to stir for 3-24 h.  
Copper iodide dimethyl sulfide complex (2). A dry 5 L 3-neck round-bottom-flask 
(w/overhead stir) was charged with copper iodide (79 g, 0.42 mol) in 2 L of anhyd THF. Dimethyl 
sulfide (25.8 g, 30.72 mL, 0.42 mol) was added to the solution at rt, and the solution was then 
cooled to –60 °C.   
4-Methyl-3-[1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone (3). The copper iodide dimethyl 
sulfide (2) mixture was cooled to -60 °C and methylmagnesium iodide solution (1) was added to 
the flask. The mixture was warmed to –10 to 0 °C and was allowed to stir for 30 min. The mixture 
was then cooled to –60 °C and azetidinone (4-Oxo-3-[1-(1,1,2,2-tetramethylpropoxy)ethyl]-2-
azetidinyl acetate) (60 g, 0.208 mol) was added to the flask. The reaction was allowed to warm to 
rt over the course of 45 min. The reaction was quenched with slow addition of satd aq NH4Cl. The 
mixture was poured into a 3 L round-bottom flask and the THF was removed. The product was 
dissolved in EtOAc and washed with 2x dilute aq NH4OH solution.  The organic layer was dried 
over Na2SO4 and concentrated in vacuo. The product was purified by silica gel flash 
chromatography via gradient elution (2.5:97.5 EtOAc/ CH2Cl2 to 40/60 EtOAc/ CH2Cl2) to afford 
3 (50 g, 83% yield) as a white solid. 
 1H NMR (400 MHz, CDCl3): δ 6.38 (s, 1H), 5.29 (s, 1H), 4.19 (m, 1H), 3.83 (m, 1H), 2.69 (m, 
1H), 1.3 (dd, J= 54 Hz, 3H), 0.86 (s, 9H), 0.067 (S, 6H).  
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13C NMR (100 MHz, CDCl3): δ 168.99, 65.74, 65.50, 47.88, 25.74, 25.59, 22.33, 20.59, 17.77, -
4.34, -4.62, -4.75.  
IR: 3415.79, 3229.86, 2959.39, 2929.27, 2893.85, 2857.09, 2708.17, 2249.20, 1754.52, 1471.48, 
1462.92, 1446.72, 1378.34, 1347.43, 1333.39, 1299.97, 1254.06, 1187.16, 1143.14, 1096.71, 
1037.92, 1005.93, 986.68, 956.49, 909.25, 835.17, 809.60, 766.45, 734.96, 661.74, 646.36.  
 2-Methyl-4-oxo-3-[1-( t-butyldimethylsilyloxy)ethyl)ethyl]-2-azetidinyl acetate (4). A dry 
100 mL round-bottom flask (w/ stir bar) was charged with compound 3 (5 g, 20 mmol) in 70 mL 
of dry EtOAc. The solution was subsequently treated with sodium acetate (1.5 g, 18.3 mmol, 0.9 
eq), acetic acid (11.55 g, 11 mL,192 mmol, 9.6 eq) and ruthenium trichloride (dried using a Bunsen 
burner under vacuum) (0.3g, 1.44 mmol, 7 mol%). The flask was cooled to 12-15 °C and oxygen 
pressure (12 psi) was applied to the reaction. Acetaldehyde (11.8 g, 15 mL, 268 mmol, 13.4 eq) 
was freshly distilled twice and added via syringe. The reaction was monitored by NMR. Once 
completed, the reaction was poured into cold hexane (1L). The mixture was extracted with cold 
hexane and washed with cold satd aq NaCl until the pH reached 7. The organic layer was dried 
over Na2SO4 and evaporated in vacuo to afford 4 (4.55 g, 91% yield) as a purple oil form. 
1H NMR 
(400 MHz, CDCl3): δ 7.05 (S, 1H), 4.31 (m, 1H), 3.05 (d, J= 9.2 Hz, 1H), 2.04 (s, 3H), 1.82 (s, 
3H), 1.33 (d, J= 6Hz, 3H), 0.86 (s, 9H), 0.067 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 170.22, 166.39, 88.61, 70.25, 68.75, 67.32, 64.69, 25.49, 21.90, 
19.69, 17.64, 0.82, -3.98, -4.41.  
IR: 3327.71, 2957.92, 2931.39, 2887.40, 2858.22, 2253.32, 1781.31, 1472.47, 1463.20, 1416.50, 
1362.49, 1254.34, 1222.80, 1171.03, 1092.37, 1015.43, 963.78, 914.20, 835.01, 812.13, 778.15, 
733.78, 647.79.  
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(p-Nitrophenyl)methyl 2-diazo-3-( t-butyldimethylsilyloxy)-3-butenoate (5). A dry 1 L round-
bottom flask (w/ stir bar) was charged with p-nitrobenzyl-2-diazoacetoacetate (52.6 g, 0.2 mol) in 
400 mL dry CH2Cl2, and the flask was cooled to 0 °C. Triethylamine (40 mL, 0.29 mol, 1.4 eq) 
was added to the flask and TBS-OTf (63.44g, 55 ml, 0.24 mol, 1.2 eq) was added. The reaction 
was warmed to room temperate and allowed to stir until completed. Once completed, the solution 
was washed three times with ice water. The organic layer was dried over Na2SO4, evaporated in 
vacuo and further dried under high vacuum overnight. 
1H NMR (400 MHz, CDCl3): δ 7.92 (dd, J= 287 Hz, 8.4 Hz 4H), 5.31 (s, 2H), 4.98 (s, 1H), 4.98 
(s, 1H), 0.86 (s, 9H), 0.07 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 163.64, 160.90, 147.91, 147.69, 143.04, 142.18, 140.29, 128.62, 
128.28, 123.96, 123.82, 90.56, 65.34, 64.73, 28.25, 25.60, 25.52, 18.04, 17.93, -3.64, -4.84. 
IR: 2929.35, 2858.14, 2138.91, 2109.84, 1698.47, 1667.19, 1603.85, 1522.60, 1453.29, 1385.52, 
1344.24, 1297.1254, 1153.99, 1109.18, 1082.80, 837.67, 739.32.  
(p-Nitrophenyl)methyl2-diazo-4-{2-methyl-4-oxo-3-[1-( t-butyldimethylsilyloxy)ethyl]-2-
azetidinyl}acetoacetate (6). A dry 100 mL round-bottom flask (w/ stir bar) with a reflux 
condenser was charged with compound 4 (3 g, 10.4 mmol) and compound 5 (5.9 g, 15.6 mmol, 
1.5 eq) in 25 mL dry CH2Cl2. 1M ZnCl2 in ether (7.3 mL, 7.28 mmol, 0.7 eq) was added to the 
reaction and the flask was heated to 42 °C for 20 min at reflux. Once completed, the reaction was 
cooled to rt and then diluted with EtOAc. The solution was washed with sated aq NaHCO3 once 
and extracted with EtOAc twice. The organic layer was dried over Na2SO4 and evaporated in 
vacuo. The crude material was purified by silica gel flash chromatography via gradient elution 
(2.5:97.5 EtOAc/ CH2Cl2 to 40/60 EtOAc/ CH2Cl2) to afford 6 (0.92 g, 31% yield) as solid.  
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1H NMR (400 MHz, CDCl3): δ 7.92 (dd, J= 287 Hz, 8.4 Hz 4H), 6.38 (s, 1H), 5.35 (d, J= 14Hz, 
2H), 4.27 (t, J= 2.8 Hz, 1H), 3.59 (dd, J= 292 Hz, 16.8 Hz, 2H), 2.85 (s, 1H), 1.538 (s, 3H), 1.40 
(d, J=12, 3H), 1.33 (t, J= 13.6 Hz, 2 H), 0.085 (s, 9H), 0.866 (S, 6H).  
13C NMR (100 MHz, CDCl3): 189.84, 167.09, 160.56, 147.85, 141.95, 128.66, 128.56, 123.88, 
123.81, 66.80, 65.43, 65.21, 55.71, 49.90, 25.69, 25.33, 22.29, 21.15, 19.78, 17.76, -3.30, -4.82.  
(p-Nitrophenyl)methyl2-diazo-4-[3-(1-hydroxyethyl)-2-methyl-4-oxo-2-
azetidinyl]acetoacetate (7). A 50 mL round-bottom flask (w/ stir bar) was charged with 
compound 6 (2g, 7.8 mmol) in 20 mL of dry acetonitrile, and 1 mL of HF was added. The reaction 
was stirred at rt. Once completed (1-3 h), finely ground NaHCO3 was added to the reaction to 
attain pH= 7. The reaction was filtered to remove the NaF and evaporated in vacuo to afford 7 (1.4 
g, 71% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J= 280 Hz, 8.3 Hz, 4H), 5.34 (q, J=18.4 Hz, 13.2 Hz, 
2H), 4.84 (s, 1H), 4.39 (m, 1H), 3.22 (d, J= 10` Hz, 1H), 2.7 (dd, J= 44.4, 18 Hz, 2H), 1.63 (s, 3H), 
1.42 (d, J= 6.4 Hz, 3H), 0.89 (s, 1H), 0.085 (s, 2H). 
13C NMR (100 MHz, CDCl3): δ 190.53, 167.18, 160.14, 147.43, 141.86, 128.37, 123.50, 65.32, 
63.51, 54.89, 49.67, 49.07, 48.64, 48.00 21.24, 20.29.  
IR: 3362.70, 2969.02, 2143.11, 1722.43, 1648.53, 1522.75, 1347.90, 1306.60, 1216.14, 1127.81, 
1025.25, 853.56, 739.51.  
(p-Nitrophenyl)methyl6-(1-hydroxyethyl)-5-methyl-3,7-
dioxoazabicyclo[3.2.0]heptane-2-carboxylate (8). A 100 mL round-bottom flask (w/ stir bar) 
with a reflux condenser was charged with compound 7 (1.3g, 3.33 mmol) and Rh2(OAc)4 (35 mg, 
0.08 mm, 0.024 eq) in 50 mL dry EtOAc. The reaction was heated to 60 °C for 30 min. Once 
completed, reaction was cooled to room temperature and was evaporated in vacuo.  
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1H NMR (400 MHz, CDCl3): δ 7.96 (dd, J= 232 Hz, 8.4 Hz, 4H), 5.31 (q, J= 19.6 2H), 4.15 (q, J= 
8 Hz, 1H), 3.68 (q, J= 10 Hz, 1H), 3.18 (d, J= 4Hz, 1H), 2.65 (dd, J= 40 Hz, 20 Hz, 1H)), 2.08 (s, 
3H), 1.55 (dd, J= 30 Hz, 15 Hz, 3H), 1.45 (d, J= 15 Hz, 1H), 1.28 (m, 1H).  
(p-Nitrophenyl)methyl6(S)-6-[(R)-1-hydroxyethyl]-3-{(3S,5S)-5-(dimethylamino)carbonyl-
1-[(p-nitrophenyl)methyl]-3-pyrrolidinylthio}-5-methyl-7-oxoazabicyclo[3.2.0]hept-2-ene-2-
carboxylate (9). A 50 mL round-bottom flask (w/ stir bar) was charged with compound 8 (1.3g, 
3.59 mmol) in 10 mL of dry CH3CN and was cooled to -35 °C. Diphenyl phosphoryl chloride (0.93 
g, 0.72 mL, 3.59 mmol, 1 eq) was then added to the flask followed by a slow addition of N,N-
diisopropylethylamine (0.45 g, 3.5 mmol, 1 eq), and the reaction was allowed to stir for 30 minutes. 
Once completed, 4-nitrobenzyl (2S,4S)-2-(dimethylcarbamoyl)-4-mercapto-1-
pyrrolidinecarboxylate (1.26 g, 0.9 mL, 3.59 mmol, 1 eq) and an additional 1 eq of DIPEA was 
added. Once completed, the reaction was extracted with CH2Cl2 and washed with satd aq NH4Cl. 
The resultant solution was then evaporated in vacuo to afford 9 (1.1 g, 85% yield) as solid. 
 1H NMR (400 MHz, CDCl3): δ 8.25 (d, J= 8.8 Hz, 2H), 7.67 (d, J= 8.4 Hz, 2H), 7.50 (dd, J= 28.8 
Hz, 8.4 Hz, 2H), 5.54 (d, J= 13.6 Hz, 2H), 5.24 (m, 1H), 4.74, (m, 1H), 4.31 (m, 1H), 3.57 (m, 
1H), 3.25 (dd, J= 56 Hz, 14.4 Hz, 2H), 3.09 (dd, J= 78 Hz, 4 Hz, 6H), 2.8 (m, 1H), 1.99 (m, 1H), 
1.62 (d, J= 6 Hz, 3H), 1.45 (d, J= 6 Hz, 3H).  
IR: 3429.25, 3114.77, 3080.51, 2970.22, 1773.76, 1708.32, 1648.96, 1606.81, 1520.54, 1429.55, 
1403.63, 1375.21, 1345.86, 1287.63, 1208.91, 1173.33, 1149.68, 1111.84, 1046.69, 1014.02, 
853.63, 853.63, 803.04, 778.75, 765.87, 736.85, 684.52.  
(6S)-6-[(R)-1-Hydroxyethyl]-3-[(3S,5S)-5-(dimethylamino)carbonyl-3-pyrrolidinylthio]-5-
methyl-7-oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (10). A 100 mL round-bottom flask (w/ 
stir bar) was charged with compound 9 (0.55 g, 0.79 mmol) in 80 mL of dry EtOAc and 40 mL of 
 
 66 
pH6 phosphate buffer solution (0.3 M). After compound 9 was dissolved, 10% Pd on carbon (0.55 
g, 5.2 mmol, 6.6 eq) was added, and the vessel was degassed and then subjected to hydrogen 
pressure 55 psi in a Parr hydrogenation device for 90 min. Once completed, the solution was 
filtered through celite, the aqueous layer was separated and washed with Et2O. The organic 
solvents were then removed from the aqueous layer and the product isolated by column 
chromatography on Diaion CHP20P resin.  Tubes containing the product were identified by 
inspection of the UV of each fraction, combined, and the water was partially removed in vacuo. 
The remaining aqueous solution was lyophilized to produce the purified antibiotic 10 (0.1385 g, 
25% yield) as white solid. 
 1H NMR (400 MHz, CDCl3): δ 4.85 (s, 1H), 4.60 (t, J= 8.4 Hz, 1H), 4.33 (m, 1H), 3.98 (t, J= 6.4 
Hz, 1H), 3.64 (q, J= 6.8 Hz, 1H), 3.36 (m, 2H), 3.09 (d, J= 47 Hz, 6H), 2.90 (d, J= 22 Hz, 2H), 
1.87 (m, 1H), 1.55 (s, 3H), 1.34 (d, 66 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 178.0, 170.0, 168.5, 137.5, 129.7, 66.5, 66.4, 63.00, 60.5, 58.8, 
52.0, 47.6, 41.7, 37.5, 36.5, 36.4, 22.0, 21.5. 
 (p-Nitrophenyl)methyl (6S)-6-[(R)-1-hydroxyethyl]-3-(diphenylphosphate) -5-methyl-7-
oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (11).  A 50 mL round-bottom flask (w/ stir bar) 
was charged with compound 8 (1.2 g, 3.31 mmol) in 10 mL of dry CH3CN and was cooled to -
35 °C. Diphenyl phosphoryl chloride (0.86 g, 0.66 mL, 3.31 mmol, 1 eq) was added to the flask 
followed by a slow addition of N,N-diisopropylethylamine (0.42g, 0.56 mL, 3.31 mmol, 1 eq). 
Once completed, the reaction was washed with aqueous NH4Cl and extracted with CH2Cl2, and 
then evaporated in vacuo. The crude material was purified by silica gel flash chromatography via 
gradient elution (0.5/99.5 MeOH/CH2Cl2 to 6/96 MeOH/ CH2Cl2) to afford 11 (0.92 g, 31% 
yield) as solid.  
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1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J= 236 Hz, 4 Hz, 4H), 7.30 (dd, J= 63 Hz, 6.8 Hz, 4 Hz, 
10H), 5.36 (dd, J= 82 Hz, 14 Hz, 2 H), 4.25 (m, 1H), 3.15 (d, J= 173 Hz, 21 Hz, 2H), 3.16 (d, J= 
10 Hz, 1H), 1.74 (d, J= 10 Hz, 1H), 1.58 (s, 3H), 1.43 (d, J= 18.4 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 176.42, 159.18, 152.42, 150.03, 147.62, 142.83, 129.93, 128.42, 
126.03, 123.78, 120.17, 117.47, 68.58, 65.28, 64.68, 59.73, 45.18, 22.68, 21.63, 1.12. 
IR: 3455.73, 1778.25, 1724.91, 1637.25, 1522.40, 1488.46, 1345.79, 1297.66, 1194.34, 1012.38, 
971.78, 851.65, 773.25. 
 (p-Nitrophenyl)methyl(6S)-6-[(R)-1-hydroxyethyl]-3-(ethylthio)-5-methyl-7-
oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (12). A 10 mL tube with 4 mL of anhyd THF was 
cooled to -78°C and was charged with ethanethiol (0.20g, 0.30 mL, 3.175 mmol, 2.5 eq) followed 
by nBuLi (0.49 ml, 1.27 mmol, 1 eq). The mixture was allowed to stir for 15 minutes. A separate 
25 mL round-bottom flask (w/ stir bar) was charged with compound 11 (0.75 g, 1.27 mmol) in 10 
mL of dry CH3CN. The 10 mL tube-mixture was added to the flask slowly. Once completed, the 
reaction was diluted with EtOAc and washed once with satd aq NH4Cl and once with satd aq 
NaHCO3. The resultant solution was evaporated in vacuo to afford 12 (0.25 g, 33% yield) as solid.  
1H NMR (400 MHz, CDCl3): δ 8.05 (dd, J= 224 Hz, 8.4 Hz, 4H), 5.41 (dd, J= 128 Hz, 14 Hz, 2H), 
4.30 (m, 1H), 3.11 (dd, J= 138 Hz, 17.6 Hz, 1H), 3.23 (d, J= 10Hz, 1H), 2.95 (d, J= 10 Hz), 3.9 
(m, 2H), 1.69 (s, 3H), 1.45 (d, 6 Hz, 3H), 1.37 (t, 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 174.92, 160.99, 149.97, 147.48, 143.28, 128.00, 123.69, 121.68, 
76.66, 67.79, 65.08, 64.98, 60.93, 48.57, 26.56, 22.64, 21.24, 14.81.  





carboxylate (13). A 100 mL round-bottom flask (w/stir bar) was charged with compound 12 (0.25 
g, 0.59 mmol) in 25 mL of EtOAc and 10 mL of pH 6 phosphate buffer solution (0.3 M). After 
solution was dissolved, 10% Pd on carbon (0.3 g, 2.8 mmol, 4.7eq) was added, and the vessel was 
degassed and then subjected to hydrogen pressure 55 psi in a Parr hydrogenation device for 90 
min. Once completed, the solution was filtered through celite, the aqueous layer was separated and 
washed with Et2O. The organic solvents were then removed from the aqueous layer in vacuo, and 
the product isolated by column chromatography on Diaion CHP20P resin. Tubes containing the 
product were identified by inspection of the UV of each fraction, combined, and the water was 
partially removed in vacuo. The remaining aqueous solution was lyophilized to produce the 
purified antibiotic 13 (15.7 mg, 6.4% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 4.94 (s, 1H), 4.33 (m, 1H), 3.14 (dd, J= 117 Hz, 6.8 Hz, 2H), 2.82 
(m, 1H), 1.51 (s, 3H), 1.34 (d, J= 6 Hz, 3H), 1.28 (t, j= 7.6 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 191.14, 181.55, 154.21, 140.66, 78.60, 76.99, 73.72, 59.56, 38.47, 
33.98, 32.43, 27.41, 9.83.  
Ethylmagnesium iodide (14). A dry 500 mL- 3-neck round bottom flask. (w/ stir bar) with a 
reflux condenser was charged with magnesium turnings (30.5g, 1.26 mol, 1.5 eq) and a catalytic 
amount of iodine crystals in 200 mL of anhyd Et2O. A solution of ethyl iodide (130 g, 67 mL, 
0.835 mol) in Et2O was added to the solution dropwise at a rate to maintain gentle reflux.   
(3S)-3-[(R)-1-( t-butyldimethylsilyloxy)ethyl]-4-ethyl-2-azetidinone (15). The copper iodide 
dimethyl sulfide (2) mixture was cooled to -60 °C and ethylmagnesium iodide (14) was added to 
the flask. The mixture was warmed to –10 °C and was allowed to stir for 5 minutes. The flask was 
cooled to -60 °C and acetate Azetidinone (60g, 0.209 mmol) was added to the flask. Once the 
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reaction completed, it was warmed to room temperature. The reaction was quenched with slow 
addition of satd aq NH4Cl. The mixture was poured into a 3 L round-bottom flask and evaporated 
in vacuo. The product was dissolved in EtOAc and washed with dilute NH4OH. The EtOAc layer 
was dried over Na2SO4 and evaporated. The product was then purified by silica gel flash 
chromatography via gradient elution (2.5:97.5 EtOAc/CH2Cl2 to 40/60 EtOAc/ CH2Cl2) to afford 
15 (48.7 g, 81% yield) as a white solid.  
1H NMR (400 MHz, CDCl3): δ 5.32 (s, 1H), 2.5 (m, 1H), 2.14 (s, 1H), 1.87 (t, j= 3.2 Hz, 3H), 1.26 
(q, j= 2.4 Hz, 2H), 0.92 (s, 9H), 0.094 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 169.20, 65.66, 63.92, 52.69, 27.98, 25.88, 22.75, 22.74, 17.94, 
10.70, -4.26, -4.91.  
IR: 3311.64, 2931.54, 2886.10, 2857.70, 2739.21, 2709.67, 1782.31, 1464.07, 1369.46, 1251.31, 
1160.75, 1102.39, 1016.07, 990.17, 945.01, 885.89, 834.36, 812.53, 776.38, 752.23, 660.51. 
 (3R)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-ethyl-4-oxo-2-azetidinyl acetate (16). A dry 
500 mL round-bottom flask (w/ stir bar) was charged with compound 15 (10 g, 38.8 mmol) in 280 
mL of dry EtOAc. The solution was subsequently treated with sodium acetate (1.8 g, 22.0 mmol, 
0.6 eq), acetic acid (23.1 g, 22 mL, 384 mmol, 9.9 eq) and ruthenium trichloride (dried using a 
Bunsen burner under vacuum) (3 g, 14 mmol, 37 mol%) was added to the flask. The flask was 
then cooled to 12-15 °C and oxygen pressure (12psi) was applied to the reaction. Acetaldehyde 
(23.6 g, 30 mL, 536 mmol, 13.8 eq) was freshly distilled twice and added via syringe. The flask 
was kept closed at all times. Once completed, the reaction was poured into cold hexane. The 
mixture was extracted with cold hexane and washed with iced satd aq NaCl until pH reached 7. 
The organic layer was dried over Na2SO4 and evaporated in vacuo to afford 16 (4.55 g, 91% yield) 
as purple oil form.  
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1H NMR (400 MHz, CDCl3): δ5.89 (s, 1H), 4.29 (m, 1H), 2.64 (q, J= 0.8 Hz, 2H), 1.27 (d, j= 3Hz, 
3H), 1.05 (t, J= 3.2 Hz, 3H), 0.873 (s, 9H), 0.088 (s, 6H).  
13C NMR (100 MHz, CDCl3): 170.38, 166.22, 90.01, 66.10, 64.47, 28.77, 25.51, 22.21, 21.52, 
17.72, 9.02, 0.84, -4.13, -4.76.  
IR: 3092.33, 2963.11, 2927.92, 2895.10, 2853.16, 2282.96, 1754.39, 1710.67, 1463.12, 1444.34, 
1381.09, 1369.22, 1348.24, 1332.02, 1300.65,1252.41, 1185.02, 1139.74, 1099.13, 1066.49, 
1047.11, 961.20, 835.24, 807.11, 775.92, 739.17, 714.54, 662.98. 
(p-Nitrophenyl)methyl2-diazo-4-{2-ethyl-4-oxo-3-[1-( t-butyldimethylsilyloxy)ethyl]-2-
azetidinyl}acetoacetate (17). A dry 250 mL round-bottom flask (w/stir bar) with a reflux 
condenser was charged with compound 16 (10 g, 38.85 mmol) and compound 5 (21.2g., 56.5 mmol, 
1.5 eq) in 50 mL dry CH2Cl2. 1M ZnCl2 in Et2O (27 mL, 27.7 mmol, 0.7 eq) was added to the 
reaction and the flask was heated to 48 °C. Once completed, the reaction was cooled to room 
temperature and then diluted with EtOAc. The solution was washed with satd aq NaHCO3 once 
and extracted with EtOAc twice. The organic layer was dried over Na2SO4 and then evaporated in 
vacuo. The crude material was purified by silica gel flash chromatography via gradient elution 
(2.5:97.5 EtOAc/ CH2Cl2 to 40/60 EtOAc/ CH2Cl2) to afford 17 (3.9 g, 39% yield) as solid.   
1H NMR (400 MHz, CDCl3): δ 7.93 (d, J= 282 Hz, 20.4 Hz, 4 H), 6.21 (s, 1H), 5.36 (d, J= 36.8 
Hz, 2 H), 4.29 (m, 1 H), 3.74 (dd, J = 343 Hz, 14.8 Hz, 2 H), 3.14 (d, J= 8.8 Hz, 1 H), 2.02 (q, J= 
7.6 Hz, 1H), 1.90 (q, J = 7.6 Hz, 1 H), 1.34 (d, J= 36.8 Hz, 3H), 1.26 (t, J = 7.2 Hz, 3H), 0.932 (s, 
9H), 0.138 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 199.20, 189.52, 168.88, 167.61, 160.90, 147.94, 141.85, 128.63, 
123.95, 65.73, 61.61, 59.41, 52.50, 46.92, 27.89, 25.69, 22.64, 22.68, 17.82, 10.60, 8.05, 0.92, -
3.33, -4.36.  
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IR: 3258.47, 2958.53, 2930.65, 2884.27, 2856.98, 2140.77, 1751.98, 1651.27, 1608.18, 1525.54, 
1471.60, 1462.71, 1375.46, 1347.80, 1258.48, 1214.02, 1188.42, 1103.18, 1039.56, 987.42, 
957.23, 896.93, 834.10, 811.33, 776.83, 739.51. 
(p-Nitrophenyl)methyl2-diazo-4-[3-(1-hydroxyethyl)-2-ethyl-4-oxo-2-
azetidinyl]acetoacetate (18). A 100 mL round-bottom flask (w/ stir bar) was charged with 
compound 17 (6g, 7.8 mmol) in 20 mL of acetonitrile, and 1 mL of HF was then added. The 
reaction stirred at rt and monitored by TLC. Once completed, finely ground NaHCO3 was added 
to the reaction to retain pH = 7. The reaction was filtered to remove the NaF and evaporated in 
vacuo to afford 17 (2.34 g, 39% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 7.90 (dd, J= 289 Hz, 8.5 Hz, 4H), 5.35 (s, 2H), 4.23 (m, 1H), 3.35 
(dd, J= 260 Hz, 18.4 Hz, 2 H), 2.05 (m, 1H), 1.88 (m, 1H), 1.35, (d, J= 4 Hz, 3H), 0.92 (t, J= 7 Hz, 
3H).  
13C NMR (100 MHz, CDCl3): δ 190.98, 167.27, 160.44, 147.99, 141.88, 128.82, 124.02, 66.76, 
65.74, 63.57, 58.61, 46.13, 26.04, 21.85, 8.57.  
IR: 3457.32, 2967.10, 2348.64, 2145.69, 1722.53, 1640.10, 1607.84, 1523.19, 1347.83, 1316.92, 
1261.20, 1214.38, 1129.57, 1040.55, 1015.59, 853.38, 799.72, 738.72. 
(p-Nitrophenyl)methyl5-ethyl-6-(1-hydroxyethyl)-3,7-dioxoazabicyclo[3.2.0]heptane-2-
carboxylate (19). A dry 100 mL round-bottom flask (w/ stir bar) with a reflux condenser was 
charged with compound 18 (2.34 g, 5.79 mmol) and Rh2(OAc)4 (50 mg, 0.11 mmol, 0.019 eq) in 
40 mL dry EtOAc. The reaction was heated to 80 °C for 30 min. Once completed, reaction was 
cooled to room temperature and was evaporated in vacuo.  
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1H NMR (400 MHz, CDCl3): δ 7.94 (dd, J= 272 Hz, 88 Hz, 4 H), 5.40 (dd, J= 38 Hz, 13.2 Hz, 2 
H), 4.83 (s, 1H), 4.45 (m, 1H), 3.25 (d, J= 9.6 Hz, 1 H), 2.5 (dd, J= 158 Hz, 17.6 Hz, 2H), 1.95 (m, 
2H), 1.49 (d, J= 3.5 Hz, 3H), 1.16 (dt, J=108 HZ, 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 189.62, 167.71, 161.00, 141.95, 128.73, 124.05, 65.55, 61.71, 
52.60, 46.02, 27.46, 25.75, 22.68, 17.92, 10.70, 8.15, 1.02, -3.23, -4.26.  
(p-Nitrophenyl)methyl (6S)-6-[(R)-1-hydroxyethyl]-3-{(3S,5S)-5-(dimethylamino)carbonyl-
1-[(p-nitrophenyl)methyl]-3-pyrrolidinylthio}-5-ethyl-7-oxoazabicyclo[3.2.0]hept-2-ene-2-
carboxylate (20). A dry 50 mL round-bottom flask (w/ stir bar) was charged with compound 19 
(2.34 g, 6.22 mmol) in 30 mL of dry CH3CN and was cooled to -35° C. Diphenyl phosphoryl 
chloride (1.4 g, 1.1 mL, 6.22 mmol, 1 eq) was added to the flask followed by a slow addition 
of N,N-diisopropylethylamine (0.74 g, 1 mL, 6.22 mmol, 1 eq). Once completed, the side chain, 
4-nitrobenzyl (2S,4S)-2-(dimethylcarbamoyl)-4-mercapto-1-pyrrolidinecarboxylate (1.26 g, 0.9 
mL, 3.59 mmol, 1 eq) and an additional 1 eq of DIPEA was added. Once completed, the reaction 
was extracted with CH2Cl2 and washed with satd aq NH4Cl. The resultant solution was then 
evaporated in vacuo to afford 20 (1.8 g, 77% yield) as solid.  
1H NMR (400 MHz, CDCl3): δ 8.20 (m, 4H), 7.64 (d, J= 8.8 Hz, 2H), 7.47 (dd, J= 35 Hz, 8.8 Hz, 
2 H), 5.52 (d, J= 14 Hz, 2H), 5.22 (m, 1H), 5.18 (dd, J= 77.2 Hz, 14 Hz, 2H), 4.15 (m, 1H), 3.65 
(m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 3.09 (d, J= 78 Hz, 6H), 2.75 (m, 1H), 2.04 (m, 1H), 1.91 (m, 
2H), 1.40 (d, J= 6 Hz, 3H), 0.99 (t, J= 7.2 Hz, 3 H).  
13C NMR (100 MHz, CDCl3): δ 175.86, 170.52, 160.54, 153.49, 153.02, 147.43, 146.01, 143.75, 
143.06, 127.95, 124.34, 124.21, 123.66, 123.57, 69.04, 65.73, 65.13, 64.28, 64.17, 56.18, 55.85, 
53.80, 52.90, 45.98, 41.44, 40.70, 37.14, 36.89, 36.06, 27.60, 22.67, 7.68, 0.91.   
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IR: 3412.08, 2917.18, 2282.69, 1770.98, 1708.50, 1650.00, 1606.39, 1520.45, 1403.11, 1345.69, 
1281.09, 1206.45, 1147.09, 1110.40, 1036.35, 735.94. 
 (6S)-6-[(R)-1-Hydroxyethyl]-3-[(3S,5S)-5-(dimethylamino)carbonyl-3-pyrrolidinylthio]-5-
ethyl-7-oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (21). A parr hydrogenation vessel was 
charged with compound 20 (0.6 g, 0.86 mmol) in 30 mL of EtOAc and 30 mL of pH6 NaH2PO4 
buffer solution (0.3 M). After compound 20 was dissolved, 10 % Pd on carbon (0.6 g, 5.6 mmol, 
6.5 eq) was added, and the vessel was degassed and then subjected to hydrogen pressure 55 psi 
in a Parr hydrogenation device for 90 min. Once completed, the solution was filtered, the 
aqueous layer was separated and washed with Et2O. The organic solvents were then removed 
from the aqueous layer and the product isolated by column chromatography on Diaion CHP20P 
resin.  Tubes containing the product were identified by inspection of the UV of each fraction, 
combined, and the water was partially removed in vacuo. The remaining aqueous solution was 
lyophilized to produce the purified antibiotic 21 (0.15 g, 25% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 4.58 (s, 1H), 3.43 (m, 2H), 3.29 (d, J=17.6 Hz, 2H), 3.02 (d, J= 4.4 
Hz, 6H), 1.98 (m, 1H), 1.85 (m, 1H), 1.33 (d, J= 6.4 Hz, 3H), 0.97 (t, J= 7.2 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 182.09, 171.06, 170.79, 138.38, 134.87, 67.02, 66.44, 61.01, 54.74, 
47.27, 43.88, 39.31, 38.53, 38.05, 29.90, 214.12, 18.83, 9.83.   
(P-Nitrophenyl)methyl (6S)-6-[(R)-1-hydroxyethyl]-3-(diphenylphosphate) 
 -5-ethyl-7-oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (22). A dry 50 mL round-bottom 
flask (w/ stir bar) was charged with compound 19 (2.34g, 6.22 mmol) in 30 mL of dry CH3CN and 
was cooled to -35° C. Diphenyl phosphoryl chloride (1.4 g, 1.1 mL, 6.22 mmol, 1 eq) was added 
to the flask followed by a slow addition of N,N-diisopropylethylamine (0.74 g, 1 mL, 6.22 mmol, 
1 eq) and the reaction stirred for 30 min. Once completed, the reaction was washed with satd aq 
NH4Cl and extracted with CH2Cl2. The organic layer was dried over Na2SO4 and then evaporated 
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in vacuo. The crude material was purified by silica gel flash chromatography via gradient elution 
(0.5/99.5 MeOH/CH2Cl2 to 6/96 MeOH/CH2Cl2) to afford 22 (1.8 g, 77% yield) as solid form.  
1H NMR (400 MHz, CDCl3): δ 7.83 (dd, J= 248 Hz, 5.2 Hz, 4 H), 7.28 (m, 5H), 5.32 (dd, J= 81.2 
Hz, 4 Hz, 2H), 4.21 (m, 1H), 3.17 (d, J= 4 Hz, 1H), 3.17 (dd, J= 49.6 Hz, 4 Hz, 2H), 2.18 (s, 1H), 
2.02 (m, 1 H), 1.84 (m, 1H), 1.30 (d, J= 6 Hz, 3H), 0.923 (t, J= 4 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 177.26, 158.85, 152.25, 152.19, 149.77, 147.49, 142.64, 129.98, 
129.79, 129.52, 128.00, 126.12, 123.64, 119.93, 118.62, 118.51, 69.54, 65.16, 64.22, 62.95, 41.50, 
27.74, 22.59, 7.36.  
IR: 3330.57, 3076.23, 2973.44, 2252.61, 1762.98, 1639.31, 1590.35, 1522.95, 1489.09, 1457.42, 
1385.69, 1347.37, 1296.95, 1186.99, 1163.02, 1106.84, 1072.32, 1046.82, 1025.78, 1012.10, 
969.62, 912.30, 850.68, 776.44, 735.26, 689.20, 647.55. 
(p-Nitrophenyl)methyl(6S)-6-[(R)-1-hydroxyethyl]-5-ethyl-3-(ethylthio)-7-
oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (23). A 10 mL tube (w/ stir bar) with 1.5 mL of 
DMF was cooled to 0 °C and was charged with compound 22 (180 mg, 0.25 mmol) 
and ethanethiol (25.8 mg, 30 µl, 0.375 mmol, 1.5 eq) followed by diisopropylamine (35.9 
mg, 50 µl, 0.32 mmol, 1.3 eq). The mixture was allowed to stir for 1.5 h. Once completed, the 
reaction was diluted with EtOAc and washed once with satd aq NH4Cl and once with satd aq 
NaHCO3. The organic layer was evaporated in vacuo and purified by silica gel flash 
chromatography via gradient elution (0.5/99.5 MeOH/CH2Cl2 to 6/96 MeOH/CH2Cl2) to afford 23 
(100 mg, 56% yield) as solid form.  
1H NMR (400 MHz, CDCl3): δ 7.93 (dd, J= 224 Hz, 8.8 Hz, 4 H), 5.42 (dd, J= 122 Hz, 14 Hz, 2 
H), 4.33 (m, 1H), 3.17 (m, 2H), 2.88 (m,  2H), 1.98 (m, 2H), 1.64 (m, 1 H), 1.44 (d, J= 64 Hz, 3H), 
1.36 (t, J= 7.6 Hz, 3H), 1.03 (t, J= 7.6 Hz, 3H). 
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13C NMR (100 MHz, CDCl3): δ 176.09, 160.80, 150.08, 147.36, 143.35, 127.88, 123.62, 122.66, 
68.84, 64.88, 64.44, 64.11, 45.10, 27.65, 26.45, 22.65, 14.89, 7.71, 0.91.  
IR: 3512.85, 3079.12, 2967.46, 2932.06, 1770.02, 1697.31, 1606.26, 1545.62, 1521.00, 1459.46, 
1378.27, 1347.30, 1329.68, 1262.12, 1206.81, 1147.47, 1099.54, 1038.43, 848.90, 801.04, 737.00, 
686.66. 
(6S)-6-[(R)-1-Hydroxyethyl]-5-ethyl-3-(ethylthio)-7-oxoazabicyclo[3.2.0]hept-2-ene-2-
carboxylate75  (24). A Parr hydrogenation vessel was charged with compound 23 (185 mg,0.43 
mmol) in 20 mL of EtOAc and 20 mL of pH6 NaH2PO4 (0.3 M) buffer solution. After compound 
was dissolved, 10% Pd on carbon (0.26 g, 2.4 mmol, 5.6 eq) was added, and the vessel was 
degassed and then subjected to hydrogen pressure 55 psi in a Parr hydrogenation device for 90 
min. Once completed, the solution was filtered through celite, the aqueous layer was separated and 
washed with Et2O. The organic solvents were then removed from the aqueous layer and the product 
isolated by column chromatography on Diaion CHP20P resin. Tubes containing the product were 
identified by inspection of the UV of each fraction, combined, and the water was partially removed 
in vacuo. The remaining aqueous solution was lyophilized to produce the purified antibiotic 24 
(19.4 mg, 10 % yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 4.63 (s, 1H), 4.19 (m, 1H), 3.21 (d, 9.6Hz, 1H), 3.08 (dd, J= 54, 
18 Hz, 2H), 2.73 (m, 2H), 1.82 (m, 2 H), 1.194 (m, 6H), 0.816 (t, 5.2 Hz, 3 H).  
13C NMR (100 MHz, CDCl3): δ 192.32, 181.42, 154.19, 142.01, 83.18, 56.42, 39.96, 38.45, 35.30, 
34.17, 32.21, 19.85, 10.83.  
(p-Nitrophenyl)methyl2-diazo-4-{3-[1-(t-butyldimethylsilyloxy)ethyl]-4-oxo-2-
azetidinyl}acetoacetate (25). A dry 50 mL round-bottom flask (w/ stir bar) with reflux condenser 
was charged with 4-oxo-3-[1-(1,1,2-trimethyl-2-propenyloxy)ethyl]-2-azetidinyl acetate (6 g, 20.8 
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mmol) and compound 5 (11.8 g, 31.2 mmol, 1.5 eq) in 40 mL of dry CH2Cl2 followed by 1 M 
ZnCl2 in Et2O (14.6 ml, 14.6 mmol, 0.7 eq) and the flask was heated to 48 °C. Once completed, 
the reaction was cooled to room temperature and diluted with EtOAc. The solution was washed 
with satd aq NaHCO3. The organic layer was dried over Na2SO4 and evaporated in vacuo. The 
crude material was purified by silica gel flash chromatography via gradient elution (2.5:97.5 
EtOAc/CH2Cl2 to 40/60 EtOAc/CH2Cl2) to afford 25 (3 g, 100% yield) as yellowish solid.  
1H NMR (400 MHz, CDCl3): δ 7.89 (dd, J= 275 Hz, 8.8 Hz, 4H), 6.26 (s, 1H), 5.36 (s, 1H), 6.22 
(dd, J= 70.8 Hz, 15 Hz, 2H), 3.66 (d, J= 21.6, 1H), 3.01 (m, 1H), 2.85 (s, 1H), 1.21 (d, J= 11 Hz, 
3H), 0.867 (s, 9 H), 0.099 (s, 6H).  
(p-Nitrophenyl)methyl2-diazo-4-[3-(1-hydroxyethyl)-4-oxo-2-azetidinyl]acetoacetate (26). A 
50 mL round-bottom flask (w/ stir bar) was charged with compound 25 (3.19 g, 8.17 mmol) in 30 
mL of CH3CN followed by 1 mL of HF and the reaction was stirred for rt. Once completed, finely 
ground NaHCO3 was added to the reaction to retain pH = 7. The reaction was then filtered to 
remove the NaF and evaporated in vacuo to afford 26 (1.6 g, 50% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J= 287 Hz, 2Hz, 4H), 5.32 (d, J= 23 Hz, 2H), 4.10 (t, J= 
6.4 Hz, 1H), 3.415 (s, 1H), 3.12 (dd, J= 87 Hz, 5.6 Hz, 2H), 2.86 (d, J= 2Hz, 1H), 1.27 (d, J= 6Hz, 
1H), 0.883 (d, J= 2.8 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 190.39, 160.47, 141.87, 128.65, 123.86, 65.50, 64.94, 63.50, 49.45, 
49.24, 49.03, 48.81, 48.60, 47.15, 44.95, 20.88.  
(p-Nitrophenyl)methyl 6-(1-hydroxyethyl)-3,7-dioxoazabicyclo[3.2.0]heptane-2-carboxylate 
(27) A dry 250  mL round-bottom flask (w/ stir bar) with a reflux condenser was charged with 
compound 26 (1.64g, 4.2mmol) and Rh2(OAc)4 (45 mg, 0.1 mmol, 0.024 eq) in 100 mL EtOAc. 
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The reaction was heated to 60 °C and stirred for 30 min. Once completed, reaction was cooled to 
room temperature and was evaporated in vacuo.  
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J= 283 Hz, 8.8 Hz, 4H), 5.33 (q, J= 13.2 Hz, 2H), 4.57 
(m, 1H), 4.16 (m, 1H), 3.24 (d, J= 5.2 Hz, 1H), 2.75 (dd, J= 185 Hz, 12 Hz, 2H), 1.43 (d, J= 6.4 
Hz, 3H). 
(p-Nitrophenyl)methyl 3-diphyneyl-phosphate-(1-hydroxyethyl)-7-
oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (28). A dry 50 mL round-bottom flask (w/ stir 
bar) was charged with compound 27 (1.64g, 4.7 mmol) in 12 mL of dry CH3CN and was cooled 
to -35 °C. Diphenyl phosphoryl chloride (1.38 g, 1.1 mL,5.17 mmol, 1.1 eq) was added to the 
flask followed by a slow addition of N,N-diisopropylethylamine (0.61 g, 0.82 mL, 4.7 mmol, 1 
eq), and the reaction was stirred for 30 min. Once completed, the reaction was washed with satd 
aq NH4Cl and extracted with CH2Cl2. The organic layer was dried over Na2SO4 and evaporated 
in vacuo. The crude material was purified by silica gel flash chromatography via gradient elution 
(0.5/99.5 MeOH/CH2Cl2to 6/96 MeOH/CH2Cl2) to afford 28 (1.0 g, 61% yield) as solid form.  
1H NMR (400 MHz, CDCl3): δ 7.16 (dd, J= 235 Hz, 4.8 Hz, 4H), 7.29 (m, 10H), 5.41 (s, 1H), 5.35 
(dd, J= 71 Hz, 14 Hz, 2H), 4.24 (q, J= 6.4 Hz, 1H), 4.14 (q, J= 7.2 Hz), 3.25 (m, 1H), 2.06 (s, 1H), 
1.30 (dd, J= 35 Hz, 6.4 Hz, 3H), 1.28 (s, 1H).  
13C NMR (100 MHz, CDCl3): δ 177.51, 158.73, 152.78, 152.71, 149.74, 149.67, 149.60, 147.39, 
142.50, 129.91, 129.63, 127.99, 126.07, 123.54, 119.85, 119.84, 119.81, 118.31, 118.20, 67.22, 
65.24, 65.13, 50.97, 36.53, 21.53, 0.89.  
IR: 3338.49, 3075.45, 2981.08, 2252.36, 1944.03, 1814.40, 1744.37, 1667.35, 1591.51, 1522.67, 
1489.28, 1456.48, 1386.76, 1348.11, 1290.48, 1186.77, 1072.50, 1025.52, 1011.00, 965.93, 




(phenylsulfonyloxy)azabicyclo[3.2.0]hept-2-ene-2-carboxylate (29). A dry 500 mL round-
bottom flask (w/ stir bar) was charged with compound 28 (12 g, 33.12 mmol) in 330 mL of dry 
CH3CN and was cooled to 0° C. p-Toluenesulfonic anhydride (11.36 g, 36.1 mmol, 1.09 eq) and 
N,N-diisopropylethylamine (4.72 g, 6.36 ml, 36.4 mmol, 1.1 eq) were added to the flask, and the 
flask was stirred for an hour at  0°C.  
1H NMR (400 MHz, CDCl3): δ 8.03 (dd, J= 152 Hz, 2 Hz, 4H), 7.54 (dd, J= 80.8 Hz, 2 Hz, 4H), 
5.27 (dd, J= 69.6 Hz, 14 Hz, 2H), 4.28 (m, 1H), 3.23 (dd, 102 Hz, 10.4 Hz, 2H), 2.46 (s, 1H), 1.82 
(d, J= 16.8 Hz, 1H), 1.61 (s, 3H), 1.37 (d, J= 6.4 Hz. 3H).  
13C NMR (100 MHz, CDCl3): δ 176.77, 158.29, 151.02, 147.53, 146.44, 142.35, 131.88, 129.97, 
128.28, 127.89, 123.6, 121.31, 67.46, 65.42, 65.26, 60.35, 60.36, 60.37, 51.13, 36.48, 21.72, 14.12.  
IR: 3337.89, 2983.01, 2257.45, 1926.10, 1816.27, 1747.59, 1666.59, 1607.38, 1522.59, 1495.62, 
1448.50, 1347.96, 1318.05, 1177.42, 1096.84, 1033.61, 957.21, 912.36, 849.71, 815.64, 735.07, 
682.60, 667.72, 648.58. 
(p-Nitrophenyl)methyl 3-azido-6-(1-hydroxyethyl)-7-oxoazabicyclo[3.2.0]hept-2-ene-2-
carboxylate (30). A 500 mL round-bottom flask (w/ stir bar) with compound (29) was charged 
with 18-crown-6 (8.7 g, 33.12 mmol, 1 eq) and KN3 (8 g, 99.36 mmol, 3 eq) was allowed to stir 
for 1.5 h. The flask was taken out of the bath and was allowed to stir in room temperature for an 
hour. The reaction was diluted with EtOAc and washed once with satd aq NaHCO3. Once with 
satd aq NH4Cl. The organic layer was dried over Na2SO4 and then evaporated in vacuo. The crude 
material was purified by silica gel flash chromatography via gradient elution (50/50 
EtOAc/CH2Cl2 to 100/0 EtOAc/CH2Cl2) to afford 30 (2.6 g, 22% yield) as yellow solid. 
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 1H NMR (400 MHz, CDCl3): δ 7.94 (dd, J= 230 Hz, 6.8 Hz, 4H), 5.38 (d, J= 84 Hz, 14 Hz, 2H), 
5.31 (s, 1H), 4.26 (m, 1H), 3.26 (m, 1H), 3.16 (d, J= 12.8 Hz, 2H), 2.32 (s, 1H), 1.84 (s, 1H), 1.33 
(d, J= 12.8 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 176.37, 159.58, 147.62, 144.28, 142.89, 128.16, 123.91, 123.78, 
66.77, 65.55, 65.23, 51.18, 37.16, 21.85, 1.03.  
IR: 3476.86, 2970.94, 2348.37, 2120.05, 1754.69, 1708.23, 1606.69, 1522.84, 1347.87, 1262.97, 
1215.97, 1108.53, 852.14, 802.64, 736.65, 698.91.  
3-Amino-6-(1-hydroxyethyl)-7-oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (31). A Parr 
hydrogenation vessel was charged with compound 30 (0.615 g, 1.59 mmol) in 60 mL of EtOAc 
and 30 mL of pH6 NaH2PO4 (0.3 M) buffer solution. Then, 10% Pd on carbon (0.6 g, 5.6 mmol, 
3.5 eq) was added, and the vessel was degassed and then subjected to hydrogen pressure 55 psi in 
a Parr hydrogenation device for 90 min. Once completed, the solution was filtered, the aqueous 
layer was separated and washed with Et2O. The organic solvents were then removed from the 
aqueous layer and the product isolated by column chromatography on Diaion CHP20P resin. Tubes 
containing the product were identified by inspection of the UV of each fraction, combined, and 
the water was partially removed in vacuo. The remaining aqueous solution was lyophilized to 
produce the purified antibiotic 31 (35 mg, 5.7 % yield) as yellow solid, however, no product was 
observed. 
(p-Nitrophenyl)methyl(6S)-6-[(S)-1-hydroxyethyl]-3-amino-7-oxoazabicyclo[3.2.0]hept-2-
ene-2-carboxylate (32). A 50 mL round-bottom flask (w/ stir bar) was charged with compound 
30 (0.6 g, 1.55 mmol) in anhyd THF, followed by triethylamine (0.22 mL, 1.55 mmol, 1 eq) and 
was cooled to 0 oC. Hydrogen sulfide gas was then bubbled into the flask for five minutes. Once 
completed, mixture was diluted with EtOAc, washed once with satd aq NaHCO3 and once with 
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brine. The organic layer was dried over Na2SO4 and then evaporated in vacuo. The crude material 
was purified by silica gel flash chromatography via gradient elution (100% EtOAc) to afford 32 
(0.1 g, 17% yield) as yellow solid.  
1H NMR (400 MHz, CDCl3): δ 7.96 (dd, J= 229 Hz, 8.4 Hz, 4H), 5.38 (dd, J= 137Hz, 7.6 Hz, 2H), 
3.09 (d, J= 1.2 Hz, 2H), 2.95 (dd, J= 28.4 Hz, 8.8 Hz, 2H), 2.07 (s, 1H), 1.36 (d, J= 6Hz, 1H), 1.27 
(m, 3H).  
(p-Nitrophenyl)methyl(6S)-6-[(S)-1-hydroxyethyl]-3-acetylamino-7-
oxoazabicyclo[3.2.0]hept-2-ene-2-carboxylate (33) A 25 mL round-bottom flask (w/ stir bar) 
was charged with compound 30 (0.21 g, 0.54 mmol) in anhyd THF, followed by lutidine (0.25 mL 
2.17 mmol, 4 eq). Hydrogen sulfide gas was then bubbled into the flask for a minute. Acetyl 
chloride (0.077 mL, 1.1 mmol, 2 eq) was added to the flask. Once completed, the reaction was 
diluted with EtOAc, washed once with water, once with brine, and once with satd aq NaHCO3. 
The organic layer was dried over Na2SO4 and then evaporated in vacuo. No product was observed.  
(S)-3-[(Z)-1-(Tert-Butyldimethylsily)-1-propenyl]-4-phenyl-1,3-oxazolidin-2-one (34). A 100 
mL round-bottom flask (w/ stir bar) was charged with (S)-4-phenyl-3-propionyl-1,3-oxazolidin-2-
one (3 g, 13.7 mml) in 30 mL of dry CH2Cl2. Tert-butyldimethylsilyl trifluoromethanesulfonate 
(5.4 g, 4.7 mL, 1.5 eq) was added followed by triethylamine (2.7 g, 3.85 mL, eq) and the reaction 
was stirred for 1 h at rt. The reaction was diluted with CH2Cl2 and washed with satd aq NaHCO3. 
The organic layer was dried over Na2SO4 and evaporated in vacuo to afford 34 (3.97, 99% yield).  
1H NMR (400 MHz, CDCl3): δ 7.39 (m, 5H), 5.0 (m, 1H), 4.0 (t, J= 4Hz, 1H), 1.56 (s, 2H), 4.76 
(m, 1H), 1.6 (s, 6H), 1.511 (d, J= 4 Hz, 3H), 0.027 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 155.93, 137.58, 129.10, 128.93, 126.94, 104.34, 100.1, 70.09, 
69.64, 59.14, 25.56, 17.98, 11.59, 10.83, -3.65, -4.49, -4.72. -5.74. 
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 IR: 2956.44, 2930.44, 2859.23, 1770.53, 1688.32, 1393.85, 1362.30, 1347.09, 1319.74, 1254.78, 
1204.54, 1147.49, 1080.43, 1055.88, 946.90, 865.94, 840.70, 784.02, 699.88.  
 (S)-3-[(Z)-1-(Trimethylsilyl)-1-propenyl]-4-phenyl-1,3-oxazolidin-2-one (35). A 100 mL 
round-bottom flask (w/ stir bar) was charged with (S)-4-phenyl-3-propionyl-1,3-oxazolidin-2-one 
(3 g, 13.7 mml) in 30 mL of dry CH2Cl2. Trimethylsilyl trifluoromethanesulfonate (4.57 g, 3.8 mL, 
1.5 eq) was added followed by triethylamine (2.7 g, 3.85 mL, eq) and the reaction was stirred for 
1 h at rt. The reaction was diluted with CH2Cl2 and washed with satd aq NaHCO3. The organic 
layer was dried over Na2SO4 and evaporated in vacuo. The crude material was purified by silica 
gel flash chromatography via gradient elution (100% CH2Cl2) to afford 35 (7.0 g, 60% yield) as 
liquid form. 
1H NMR (400 MHz, CDCl3): δ 7.39 (m, 5 H), 5.05 (m, 1H), 4.75 (m, 2H), 4.05 (t, J= 4 Hz, 1H), 
3.15 (q, J= 4Hz, 1H), 1.5 (d, J= 8 Hz, 3H), 1.4 (t, J= 8 Hz, 2 H), 0.2 (s, 6 H).  
13C NMR (100 MHz, CDCl3): δ 155.13, 137.48, 137.26, 128.13, 127.95, 125.80, 125.11, 101.71, 
98.59, 69.36, 68.99, 58.46, 11.59, 10.83, -0.81, -0.1.0.  
IR: 3513.67, 3035.71, 2961.24, 2918.74, 2360.22, 2341.91, 1766.75, 1711.67, 1687.98, 1605.69, 
1494.74, 1478.67, 1458.21, 1394.38, 1348.02, 1321.39, 1254.00, 1152.39, 1057.68, 1030.40, 
946.96, 873.02, 848.63, 804.03, 760.85, 701.09, 638.62. 
3-(2-{3-[(R)-1-(Dimethyl-tert-butylsilyloxy)ethyl]-2-methyl-4-oxo-2-azetidinyl}acetyl)-1,3-
oxazolidin-2-one (36). A 10 mL tube (w/ stir bar) was charged with chiral oxazolidinone (3-
propionyl-1,3-oxazolidin-2-one) (0.56 g, 1.99 mmol, eq) in dry CH2Cl2 and was cooled to 0 
oC. 
Titanium tetrachloride (0.175 mL, 1.59 mmol, 1.6 eq) was added and the reaction was stirred for 
10 min. N, N-diisopropylethylamine (0.350 mL, 1.99 mmol, 2 eq) was added to the reaction. The 
mixture was allowed to stir for 30 min, and it was allowed to warm to room temperature. 
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Compound 4 (0.3 g, 0.995 mmol) was added to the reaction. Once completed, reaction was diluted 
with CH2Cl2 and washed with water. No product was observed.  
(Azidosulfonyl)methane (37). A 1-L round-bottom flask (w/ stir bar) was charged with 400 mL 
of acetone, and the flask was cooled to 0 oC. Methanesulfonyl chloride (14.4 mL, 186 mmol) was 
added to the cold acetone followed by slow addition of sodium azide (19 g, 0.3 mmol, 1.5 eq) in 
120 mL of water. Once competed, reaction was diluted with Et2O and washed with satd aq 
NaHCO3. The organic layer was dried over Na2SO4 and evaporated in vacuo to afford 37 (16 g, 
65% yield) in solid form.  
1H NMR (400 MHz, CDCl3): δ 3.23 (s, 3H).  
Methyl 2-diazo-3-oxovalerate (38). A 1-L round-bottom flask (w/ stir bar) was charged with 
commercial methyl propionylacetate (10 g, 9.6 mL, 76.8 mmol) in 400 mL of dry CH2Cl2 and 
triethylamine was added to the flask at rt. The reaction was cooled to 0 oC and 
(azidosulfonyl)methane was added drop wise. The reaction was allowed to stir for one hour at rt. 
Once completed, the solvent was concentrated, and the reaction was diluted with 250 mL Et2O and 
washed three times with 10% NaOH. The organic layer was dried over Na2SO4 and evaporated in 
vacuo to afford 38 in liquid form. 
1H NMR (400 MHz, CDCl3): δ 3.82 (s, 3H), 2.89 (q, J= 21.6 Hz, 7.2 Hz, 2H), 1.16 (t, J= 3 Hz, 
3H).  
13C NMR (100 MHz, CDCl3): δ 192.11, 160.96, 74.38, 51.24, 32.85, 7.23. IR: 1659.36, 1437.45, 
1364.39, 1308.12, 1219.44, 1138.15, 1081.30, 1024.53 
Methyl (Z)-2-diazo-3-(trimethylsilyloxy)-3-pentenoate (39). A 50 mL round-bottom flask (w/ 
stir bar) was charged with compound 38 (2 g, 11.3 mmol) in 25 mL of dry CH2Cl2 and 
triethylamine (2.12 mL, 15.82 mmol1.4 eq) was added to the flask at 0 oC. TMS-OTf (2.5 mL, 
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13.6 mmol, 1.2 eq) was added to the reaction mixture dropwise. The reaction was allowed to stir 
for 30 min at 0 oC. Once completed, the reaction mixture was diluted with hexane, washed with 
satd aq NaHCO3 once and washed with brine once. The organic layer was dried over Na2SO4 and 
then evaporated in vacuo to afford 39 (2.78 g, 99% yield) in liquid form. 
 1H NMR (400 MHz, CDCl3): δ 5.35 (q, J= 7.2 Hz, 1H), 3.797 (s, 3H), 1.69 (d, J= 6.8 Hz, 3H), 
0.233 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 193.24, 161.71, 75.35, 52.00, 33.59, 8.09. IR: 2956.74, 2348.51, 
2147.00, 1736.56, 1438.91, 1261.18, 1200.17, 1080.48, 843.12, 801.64, 736.89.  
Methyl (Z)-2-diazo-3-(dimethyl-tert-butylsilyloxy)-3-pentenoate (40). A 50 mL round-bottom 
flask (w/ stir bar) was charged with compound 38 (2 g, 11.3 mmol) in 25 mL of dry CH2Cl2 and 
triethylamine (2.12 mL, 15.82 mmol1.4 eq) was added to the flask at 0 oC. TBS-OTf (3.12 mL, 
13.6 mmol, 1.2 eq) was added to the reaction mixture dropwise. The reaction was allowed to stir 
for 30 min at 0 oC. Once completed, the reaction mixture was diluted with hexane, washed with 
satd aq NaHCO3 once and washed with brine once. The organic layer was dried over Na2SO4 and 
then evaporated in vacuo to afford 40 (3.2 g, 99% yield) in liquid form. 
1H NMR (400 MHz, CDCl3): δ 5.28 (q, J= 4.8 Hz, 1H), 3.81 (s, 3H), 1.69 (d, J= 7.2 Hz, 3H), 0.937 
(s, 9H), 0.174 (s, 6H).  
13C NMR (100 MHz, CDCl3): δ 179.70, 172.03, 51.70, 36.98, 35.30, 33.37, 17.45, 13.83, 10.34, 
16.55, 8.26, 7.94. 
 IR: 2952.71, 2859.58, 1923.33, 1834.72, 1726.78, 1626.07, 1472.80, 1436.08, 1411.48, 1361.95, 
1255.82, 1145.84, 1042.97, 940.40, 841.00, 723.29, 693.85. 
Methyl 2-diazo-3-oxo-4-{4-oxo-3-[1-(trimethylsilyloxy)ethyl]-2-azetidinyl}valerate (41). A 
10 mL tube (w/ stir bar) was charged with compound commercial acetate (3-[(R)-1-(Dimethyl-
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tert-butylsilyloxy)ethyl]-4-oxo-2-azetidinyl acetate) (0.1 g, 0.35 mmol) in 2 mL of dry CH2Cl2 
and compound 39 (0.24g, 1.05 mmol, 3 eq) was added followed by 1 M ZnCl2 in Et2O (0.35 mL, 
0.35 mmol, 1 eq) and the reaction was heated to 45 oC. Once completed, reaction mixture was 
diluted with EtOAc, washed once with satd aq NaHCO3. The organic layer was dried over 
Na2SO4 and then evaporated in vacuo to yield 41 in oil form.  
1H NMR (400 MHz, CDCl3): δ 7.28 (s, 2H), 5.381, (s, 1H), 4.37 (m, 1H), 4.20 (m, 1H), 3.81 (s, 
3H), 1.67 (s, 6H), 1.26 (m, 6H), 0.92 (s, 9H),  
(p-Nitrophenyl)methyl 3-oxovalerate (42). A 250 mL round-bottom flask (w/ stir bar) with 
distillation device was charged with commercial methyl propionylacetate (30 g, 28.9 mL, 0.23 
mol) and (p-nitrophenyl)methanol (33.54 g, 0.219 mol) and heated to 170 oC for 24 hours. Once 
completed, the crude material was purified by silica gel flash chromatography via gradient elution 
(50/50 CH2CL2/Hexane to 100/0 CH2Cl2/Hexane then 2.5/97.5 EtOAc/CH2Cl2) to afford 42  (27 
g, 47% yield) as oil form.  
1H NMR (400 MHz, CDCl3): δ 7.81 (dd, J= 258 Hz, 5.6 Hz, 4H), 5.21 (s, 2H), 3.54 (s, 2H), 2.52 
(q, J= 6.8 Hz, 2H), 1.02 (t, J= 7 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 203.35, 166.90, 147.40, 143.52, 128.18, 123.52, 65.1348.44, 36.26, 
30.62, 7.36.  
(p-Nitrophenyl)methyl 2-diazo-3-oxovalerate(43). A 1-L round-bottom flask (w/ stir bar) was 
charged with compound 42 (27 g, 0.1075 mol) in 400 mL of dry CH2Cl2 and triethylamine was 
added to the flask at rt. The reaction was cooled to 0 oC and (azidosulfonyl)methane was added 
slowly. The reaction was allowed to stir for one hour at rt. Once completed, the solvent was 
concentrated, and the reaction was diluted with 250 mL Et2O and washed three times with 10% 
NaOH. The organic layer was dried over Na2SO4 and evaporated in vacuo to afford 43 in oil form.  
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1H NMR (400 MHz, CDCl3): δ 8.38 (d, J= 7.2 Hz, 2H),7.95,(d, J= 6.8 Hz, 2H), 5.33 (s, 2H), 2.80 
(q, J= 8 Hz, 2H), 1.06 (t, J= 8 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 192.58, 160.69, 147.55, 142.26, 128.36, 123.62, 75.14, 65.02, 
33.52, 7.87.  
(4-Nitro-2,4,6-cycloheptatrien-1-yl)methyl (E)-2-diazo-3-(trimethylsilyloxy)-3-pentenoate 
(44). A 250 ml round-bottom flask (w/ stir bar) was charged with compound 43 (8 g, 36.7 mmol) 
in 80 mL of CH2Cl2 and triethylamine (6.8 mL, 51.33 mmol, 1.4 eq) was added to the flask at 
0oC. TMS-OTf (7.96 mL, 44.00 mmol, 1.2 eq) was then added slowly to the flask at 0oC. Once 
completed, the reaction was washed with satd aq NaHCO3 and once with sat brine. The organic 
layer was dried over Na2SO4 and then evaporated in vacuo. the crude material was purified by a 
short silica gel flash chromatography (DCM) to afford 44 (4 g, 50% yield) as yellowish/orange 
solid.  
1H NMR (400 MHz, CDCl3): δ 8.12 (d, J= 8 Hz, 2H), 7.47 (d, J= 8Hz, 2H), 5.285 (m, 3H), 1.62 
(d, J= 8 Hz, 3H), 0.23 (s, 9H).  
13C NMR (100 MHz, CDCl3): δ 163.84, 147.33, 143.01, 132.17, 127.92, 123.43, 106.43, 64.58, 
64.50, 11.53, -0.28, -0.42., 1006.31, 843.33, 802.82, 733.83, 668.61.  
IR: 3296.58, 2981.78, 2957.04, 2880.38, 2848.98, 2605.60, 2523.25, 2425.07, 2348.69, 2254.13, 
2144.43, 1724.38, 1658.35, 1437.77, 1364.63, 1308.02, 1219.17, 1137.95, 1081.23, 1024.48, 
975.48, 919.49, 798.68, 743.53, 699.09, 647.84. 
 (4-Nitro-2,4,6-cycloheptatrien-1-yl)methyl 4-{(2R,3S)-3-[(S)-1-(t-
butyldimethylsilyloxy)ethyl]-2-methyl-4-oxo-2-azetidinyl}-2-diazo-3-oxovalerate (45) A dry 
100 mL round-bottom flask (w/ stir bar) with a reflux condenser was charged with compound 4 
(5 g, 16.6 mmol) and compound 44 (8.4 g, 28.9 mmol, 1.7 eq) in 15 mL of dry CH2Cl2. 1M 
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ZnCl2 in Et2O (7.3 mL, 7.28 mmol, 0.7 eq) was added to the reaction, and the flask was heated to 
42 °C. Once completed, the reaction was cooled to rt and diluted with EtOAc. The solution was 
washed with sated aq NaHCO3 once and extracted with EtOAc twice. The organic layer was 
dried over Na2SO4 and evaporated in vacuo. The crude material was purified by silica gel flash 
chromatography via gradient elution (2.5:97.5 EtOAc/CH2Cl2 to 40/60 EtOAc/CH2Cl2) to afford 
44 (0.65 g, 7.5% yield) as solid. 
1H NMR (400 MHz, CDCl3): δ 8.152 (d, J= 8 Hz, 2H), 7.493 (d, J= 8 Hz, 2H), 6.980 (s, 1H), 5.295 
(m, 2H), 4.065 (m, 1H), 3.714 (m, 1H),  2.69 (d, J= 9.6 Hz, 1 H), 2.56 (d, J= 5.2 Hz, 1H), 1.95 (s, 
1H), 1.43 (s, 3H), 1.17 (d, J= 9.2 Hz, 3H), 0.798 (s, 17H). 
13C NMR (100 MHz, CDCl3): δ 193.37,170.79, 168.82, 167.60, 160.17, 147.56, 142.16, 128.73, 
123.62, 67.20, 65.54, 65.28, 65.20, 60.05, 59.37, 50.73, 46.80, 25.62, 25.44, 22.17, 21.73, 20.71, 
17.79, 17.12, 13.90, 12.98, 0.74. 
 (4-Nitro-2,4,6-cycloheptatrien-1-yl)methyl 4-{(2R,3S)-3-[(S)-1-hydroxyethyl]-2-methyl-4-
oxo-2-azetidinyl}-2-diazo-3-oxovalerate (46) A 100 mL round-bottom flask (w/ stir bar) was 
charged with compound 45 (0.65g, 0.125 mmol) in 5 mL of acetonitrile, and 1 mL of HF was 
then added. The reaction stirred at rt for 30 min and monitored by TLC. Once completed, finely 
ground NaHCO3 was added to the reaction to retain pH = 7. The reaction was diluted with 
EtOAc and washed with satd aq NaHCO3. The EtOAc was dried over Na2SO4 and evaporated to 
afford 45 (0.27 g. 53% yield) as white solid.  
1H NMR (400 MHz, CDCl3): δ 8.152 (d, J= 8 Hz, 2H), 7.493 (d, J= 8 Hz, 2H), 6.65 (s, 1H), 5.32 
(m, 2H), 4.08 (m, 1H), 3.84 (m, 1H), 3.07 (d, J= 9.6 Hz, 1 H), 2.00 (s, 1H), 1.52 (s, 3H), 1.34 (d, 
J= 7.2 Hz, 3H), 1.22, (d, J= 8 Hz, 4H).  
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13C NMR (100 MHz, CDCl3): δ 195.46, 167.44, 159.90, 147.75, 141.81, 128.63, 123.81, 65.50, 
63.71, 62.49, 60.23, 58.36, 49.39, 21.96, 20.30, 13.98, 12.29.  
IR: 3467.33, 3059.41, 2971.72, 1720.35, 1649.03, 1608.18, 1526.31, 1348.26, 1294.62, 1220.89, 
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